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Zusammenfassung 
Arterielle Hypertonie betrifft bis zu 600 Millionen Menschen weltweit. Chronisch 
erhöhter Blutdruck ist ein großer Risikofaktor für Herz-Kreislauferkrankungen. Das 
sogenannte Renin-Angiotensin System (RAS) erhält das Gleichgewicht zwischen 
gefäßverengenden und gefäßerweiternden Effekten auf den Blutkreislauf. Ein wichtiger 
Bestandteil dieses Systems ist Angiotensin II (Ang II). Dieses aus acht Aminosäuren 
zusammengesetzte Peptid wirkt gefäßverengend und induziert die Wiederaufnahme von 
Wasser aus dem Urin ins Blut. Dadurch erhöht Ang II den Blutdruck. Angiotensin (1-7) 
(Ang 1-7), ein weiteres RAS- Peptid, hingegen hat eine gegensätzliche Wirkung auf das 
Herz-Kreislaufsystem.  
Verschiedene niedermolekulare Substanzen werden eingesetzt, um die Produktion 
oder die Wirkung von Ang II zu blockieren und somit den Blutdruck zu senken. Diese 
müssen täglich eingenommen werden und zeigen nur in Kombination Effektivität. Daher 
ist es ein wichtiges Anliegen, neue effektive Therapien gegen Bluthochdruck und seine 
fatalen Folgen hervorzubringen. Die Entwicklung eines Impfstoffs gegen Ang II könnte 
hier einen wesentlichen Beitrag leisten.   
Die vorliegende Arbeit ist Teil eines Projekts, das darauf abzielt einen Peptid-
Impfstoff zu entwickeln, der es ermöglicht Ang II aus dem System zu entfernen, ohne Ang 
1-7 oder seinen Vorläufer, Angiotensin I (Ang I), anzutasten. Hierfür wurde die 
Immunogenität verschiedener Ang II-Peptid Varianten getestet, sowie deren Fähigkeit 
überprüft, Seren mit unterschiedlicher Reaktivität zu induzieren. Daten aus verschiedenen 
ELISA (enzyme linked immunosorbent assay)- Experimenten zeigen, dass Peptid- 
Varianten, auch Variotope® genannt, selektiert werden konnten, die Antikörper 
induzieren, welche eine stark reduzierte Reaktivität gegen Ang 1-7 und Ang I aufweisen, 
das Ang II Peptid jedoch nach wie vor effektiv binden. 
Ein zellulärer Assay soll weiters die Überprüfung der inhibitorischen Fähigkeit von 
Variotop®-induzierten Seren in vitro ermöglichen. Der hier entwickelte Assay basiert auf 
der Expression von Luziferase durch die Aktivierung von NF-κB in HEK293 Zellen. 
Stimulation der, zusätzlich mit einem Angiotensin II Rezeptor-GFP Konstrukt transient 
transfektierten, HEK293 Zellen mit Ang II bewirkt einen signifikanten Signal-Anstieg. Die 
große Differenz zwischen unstimuliertem und stimuliertem Zustand, ermöglicht die 
Bestimmung der blockierenden Wirkung von Ang II- Antikörpern. 
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Abstract 
Hypertension is the most prevalent risk factor for cardiovascular disease (CVD) 
and thus constitutes an important worldwide public-health challenge. The renin-
angiotensin system (RAS) maintains the balance of contractive and dilutive effects within 
the vasculature. Angiotensin II (Ang II), an octapeptide, is a potent mediator of 
vasoconstriction and anti-diuretic effects and thus elevates blood pressure. Angiotensin 
(1-7) (Ang 1-7), a heptapeptide derived from angiotensin I (Ang I) or Ang II via 
angiotensin-converting enzyme (ACE) or angiotensin-converting enzyme II (ACE2) 
respectively is known to counteract these actions. Vaccination therapies targeting a 
component of the RAS other than Ang II have so far been unsuccessful in achieving target 
blood pressure or have even induced autoimmune disease. However, a phase II clinical 
study using Ang II as a target for immunotherapy conducted has been successful in 
decreasing blood pressure levels in humans.  
AFFiRiS AG is developing a peptide-based hypertension vaccine targeting Ang II, 
while sparing Ang I and Ang 1-7 to maintain its vasodilative potential. Therefore, different 
candidates of Ang II-derived peptide-variants (Variotopes®) are evaluated for 
immunogenicity and specificity for Ang II. ELISA results show that it is possible to induce 
higher antibody titres against Ang II (a measurement for immunogenicity) while reducing 
the crossreactivity of antibodies to Ang I and Ang 1-7 with Variotopes®. The ability of 
Variotope®-induced antibodies to block the binding of Ang II to its receptor should be 
determined with a functional assay based on cell cultures. A luciferase activity assay has 
been established to measure the effects of Ang II stimulation in HEK293 cells transiently 
co-transfected with AT1R-EGFP and NFkB-luciferase expression vectors. The luciferase 
activity is significantly higher in stimulated than in un-stimulated cells, thus giving enough 
margin to determine inhibitory properties of antibodies. Furthermore, this signal increase 
could be reversed with Angiotensin II type I receptor blocker losartan. The established 
assay can be used to determine the potential correlation between antibody titre, affinity 
and functionality. 
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1. Introduction 
1.1. Cardiovascular disease (CVD) and hypertension  
According to the World Heath Organisation (WHO) approximately 30% of all global 
deaths are attributed to cardiovascular disease (CVD). Nearly every fifth person over the 
age of 15 in Austria is affected with high blood pressure 1. CVD is caused by disorders of 
the heart and blood vessels and encompasses various manifestations, including 
myocardial infarction, stroke, heart failure, and chronic kidney disease. Hypertension is 
the most prevalent risk factor for CVD and thus constitutes an important worldwide public-
health challenge. It has been identified as the leading risk factor for mortality and is ranked 
third as a cause of disability-adjusted life-years. 26.4% of the world’s adult population had 
hypertension in 2000 and international health studies project an increase of 60% in the 
total number of patients until 2025 2. Hypertension, commonly referred to as high blood 
pressure is defined as chronically elevated blood pressure with a systolic blood pressure 
above 140 mmHg and/or a diastolic blood pressure above 90 mmHg (see Figure 1 3). 
 
Figure 1:  Classification and Management of Blood Pressure for Adults Aged 18 Years or 
Older cited from Chobanian AV et al. JAMA 2003, 289: 2560-2572: The Seventh Report of the 
Joint National Committee on Prevention, Detection, Evaluation and Treatment of High Blood 
Pressure 
Lowering the blood pressure is an important strategy to prevent CVD. First steps 
towards the reduction of blood pressure are changes in life style, targeting primary factors 
like overweight, high sodium uptake through an unhealthy diet, physical inactivity, high 
alcohol consumption and smoking. However, treatment of chronic significantly elevated 
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hypertension requires specific therapies. A key regulator of the blood pressure is the 
renin-angiotensin system (RAS) which has become an attractive target for therapeutic 
intervention and treatment of hypertension.  
1.2. The renin-angiotensin system (RAS)  
The main regulator for vascular tone, fluid and electrolyte homeostasis, and blood 
pressure is the renin-angiotensin system (RAS). Circulating components of the RAS act 
as endocrine factors in order to maintain blood pressure and electrolyte as well as fluid 
balance. In addition to this circulating RAS, the so-called tissue RAS can function locally 
as paracrine and/or autocrine factor. This enables the local RAS system to cooperate with 
circulating RAS factors, but also allows it to operate independently of its circulating 
counterpart. 
The RAS pathway is a cascade of protein conversions beginning with the cleavage 
of angiotensinogen (AGT) by renin. AGT is mainly generated and constitutively secreted 
into the circulation by hepatocytes. Renin is an aspartyl protease synthesised in and 
secreted from the granules of juxtaglomerular cells in the kidney. It has high substrate 
specificity for AGT, cleaving this precursor protein at its N-terminus to produce the inactive 
peptide angiotensin I (Ang I). The decapeptide Ang I, is rapidly processed by angiotensin-
converting enzyme (ACE) to angiotensin II (Ang II) 4. ACE is a membrane-bound 
metalloproteinase expressed on the surface of endothelial cells with the highest 
concentrations found on the vascular epithelium in the lung. Besides ACE, chymase and 
other enzymes such as tonin and cathepsin have been shown to produce Ang II from Ang 
I. In contrast to its precursor-peptide, Ang II shows high biological activity. Additionally, 
other Ang I- and Ang II-derived, functional peptides can be found in the circulation. These 
are generated by amino-, carboxy- or endopeptidases and include Ang (1-9), Ang (1-7), 
Ang III (the 2-8 peptide) and Ang IV ( the 3-8 peptide).  
Ang II, an octapeptide, regulates the body’s fluid and sodium balance, the blood 
pressure, cellular growth and cardiovascular remodelling and is thus considered the main 
effector of the RAS. The actions of Ang II are predominantly mediated by two G-protein-
coupled seven transmembrane receptors, the Ang II type 1 receptor (AT1R) and the Ang II 
type 2 receptor (AT2R). The AT1 and AT2 receptor subtypes bind Ang II similarly, but have 
a different cellular localization, are differentially expressed in diverse tissues and are 
thought to mediate opposite functions. Most of Ang II hypertensinogenic actions are 
attributed to the AT1 receptor (see Figure 2 5).  
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The activation of the AT1 receptor on vascular smooth muscle cells (VSMC) leads 
to vasoconstriction throughout the whole body. Thereby, Ang II increases systemic arterial 
blood pressure and decreases the blood flow. This is also mediated by the induction of 
fibrosis, cellular growth and migration, and the generation of reactive oxygen species 
(ROS) by Ang II signalling through AT1R. In the adrenal cortex, Ang II causes the release 
of aldosterone which leads to increased re-absorption of sodium and water in the kidneys. 
Ang II also acts on the central nervous system inducing a feeling of thirst. Additionally, 
Ang II stimulates the release of Anti Diuretic Hormone (ADH), also called vasopressin. 
Vasopressin normally acts in cases of dehydration, where it signals the kidney to increase 
the reuptake of water from the urine and to increase peripheral vascular resistance. Thus 
it also leads to increased arterial blood pressure 5. The molecular mechanisms of AT1R 
signalling are described in the next part of the introduction.  
The AT2 receptor is located on the X chromosome in humans and rodents and 
shares only 34% identity with its AT1R counterpart. Furthermore, the AT2 receptor is 
clearly distinct from the AT1 receptor concerning tissue-specific expression and signalling 
mechanisms. The AT1R is expressed in the heart, the kidney, the lung, the aorta, the liver, 
in testis and ovary, the adrenal and the pituitary gland in the brain. However, it is most 
abundantly expressed in vascular smooth muscle cells. AT1R expression is stimulated by 
glucocorticoids and depends on the activity of the RAS. In most adult tissues, AT2R is also 
expressed, though to a much lesser extent than AT1R. Some fetal tissues, however, 
express AT2R at high levels. Levels of AT1R expression, in contrast, are not age- or 
development- dependent. AT2R expression is found to be up-regulated in the non-
Figure 2: Angiotensin receptor type I 
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pregnant uterus and in pathological circumstances, such as cardiac hypertrophy, 
myocardial infarction, cardiomyopathy and congestive heart failure. In these pathologic 
conditions, the AT1 receptor is significantly down-regulated. The AT2 receptor also 
emerges during wound healing of the skin. In the kidney, AT2R is predominantly 
expressed in embryonic mesenchymal cells that undergo apoptosis and are replaced by 
tubular tissue during development. However, the level of AT2R expression is dramatically 
decreased in adult tissues. The liver and the pituitary gland are completely devoid of 
AT2R. It is not clear how AT2R expression and activity are regulated, but it is assumed that 
post-transcriptional and/or translational modulation is involved in these processes 5. 
However, the AT2 receptor lacks internalisation and desensitisation mechanisms and thus 
is thought to maintain differentiated cells in a quiescent state. In contrast to the effects of 
AT1R stimulation, an activated AT2 receptor suppresses tissue and cellular growth and 
causes vasodilatation via the release of nitric oxide (NO) 4. Although, the AT2R shares the 
structural features of seven transmembrane domain receptors, it does not modulate 
cytosolic Ca2+ or cyclic AMP, does not seem to be coupled to a heterotrimeric G protein 
and thus, does not reveal any functional features characteristic for this class of receptors. 
However, AT2R might negatively modulate AT1R-mediated phospholipase C activation, 
lead to cGMP (or NO) generation and activate protein tyrosine and serine/threonine 
phosphatases 5.  Furthermore, AT2R has been found to counteract the mitogenic and the 
fibrotic action of AT1R. 
 
 
Figure 3: The two arms of the RAS pathway 
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Ang 1-7 was long thought to lack any biological activity. Recently, a second 
converting enzyme, the carboxypeptidase, angiotensin-converting enzyme II (ACE2) has 
been described to act on Ang I as well as Ang II 6 (see Figure 3). ACE inhibitors widely 
used as drugs against hypertension do not inhibit ACE2, but cause its up-regulation. The 
disruption of the ACE2 gene leads to severe cardiac contractility defects, increased Ang II 
levels and the up-regulation of hypoxia-induced genes in humans 4. ACE2 generates 
Ang1-9 from Ang I and Ang 1-7 from Ang II. Ang 1-7 can also be produced from Ang I via 
Ang1-9 by ACE2 and consecutively by ACE, in parallel to the conversion of Ang I to Ang II 
(see Figure 3). In contrast to Ang II, which elevates blood pressure and appears to be the 
major mediator of vascular remodelling and inflammation in hypertension, the Ang 1-7 
peptide promotes vasodilatation and thus may counterbalance the potentially detrimental 
actions of Ang II. In addition to a reduction in Ang II levels through Ang 1-7 production, the 
Ang 1-7 heptapeptide counteracts Ang II by causing vasodilatation, antitropic effects and 
by interacting with the prostaglandin-bradykinin-NO system. These effects of Ang 1-7 are 
thought to be mediated by its receptor, the mas oncogen product (MAS) 7. Like the 
angiotensin type 1 and type 2 receptors, the Mas receptor belongs to the family of seven 
transmembrane G-protein coupled receptors too. Many studies show that Ang 1-7 
opposes the effects of Ang II indirectly by stimulating NO and prostacyclin release. 
Interestingly, Sampaio and his group found that Ang 1-7 significantly decreases the Ang II-
stimulated activation of Nox-based nicotinamide adenosine dinucleotide phosphate 
(NADPH) oxidase by Src homology 2-containing inositol phosphatase 2 (SHP-2) 
phosphorylation in human aortic endothelial cells (HAEC). This shows that Ang 1-7 
signalling also directly interplays with Ang II stimulated signalling pathways. In fact, Ang 1-
7 has been found to antagonise Ang II-induced activation of protein kinase C and ERK1/2 
(extracellular signal related kinases), to inhibit Ang II-stimulated MAP kinase 
phosphorylation through prostacyclin-mediated production of cAMP and to reduce Ang II-
mediated phosphorylation of p38 MAP kinase and jun N-terminal kinase. However, Ang 1-
7 alone did not cause any of these effects 7.  
Ang III is produced from Ang II by aminopeptidase A and elicits similar effects as 
Ang II via AT1 and AT2 receptors. However, Ang III has a significantly higher clearance 
rate than Ang II, indicating that the latter plays a more dominant role as an effector of the 
circulating RAS. Ang IV is generated from Ang III by aminopeptidase M and acts on an 
insulin-regulated aminopeptidase receptor (IRAP), also known as AT4R. Its activation 
leads to renal vasodilatation, hypertrophy and the activation of NF-κB. Several studies 
suggest that Ang IV is an important regulator of cognition, renal metabolism and 
cardiovascular damage and is also involved in vascular inflammatory responses 4. 
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1.3 Ang II type 1 receptor signalling  
The AT1R subtype of Ang II receptors is predominantly expressed in vascular 
smooth muscle cells. The ligand binding site of this seven transmembrane receptor is 
located on the extracellular surface of the plasma membrane, while the G-protein binding 
site faces the cytosol. G-proteins consist of three subunits: α, β and γ. The α-subunit has a 
guanosine-triphosphate (GTP) binding and GTPase activity. Thereby, activated α-subunits 
regulate effector molecules such as adenylyl cyclase, and phospholipase C. The signalling 
reaction is terminated after hydrolysis of GTP to guanosine-diphosphate (GDP). After 
desensitisation, the receptor is uncoupled from the G-protein, phosphorylated and 
consequently internalised and recycled 8. The AT1 receptor interacts with multiple 
heterotrimeric G-proteins, including Gq/11, Gi, G12 and G13 and thus stimulates the 
production of second messenger molecules and ROS (reactive oxygen species). 
 
 
Stimulation of the Ang II type I receptor leads to the activation of phospholipase C-
β (PLC-β) and the subsequent formation of diacylglycerol (DAG) and inositol triphosphate 
(IP3). In cultured rat VSMCs PLC-γ is activated rather than PLC-β. DAG activates protein 
kinase C (PKC), whereas IP3 mediates the release of calcium from intracellular stores 
(smooth endoplasmatic reticulum) (see also Figure 4 10).  
Figure 4: G-protein coupled activa-
tion of phospholipase C, formation of 
diacylglycerate and activation of pro-
tein kinase C 
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Figure 5: Angiotensin II signalling via the Angiotensin II receptor type I  
In addition to this traditionally transcribed pathway, AT1 receptor stimulation also 
leads to mitogen-activated protein (MAP) kinase activation in VSMC, glomerulosa cells, 
renal mesanglial cells, cardiac myocytes and fibroblasts. This is mainly due to the Ang II-
mediated transactivation of the endothelial growth factor receptor (EGFR). Ang II-induced 
EGFR transactivation seems to be Ca2+ sensitive and requires the presence of ROS. A, so 
far unknown, kinase is thought to activate ADAM17 (a disintegrin and 
metalloproteinase17) that in turn mediates the production of an EGFR ligand, such as 
heparin-binding EGF (HB-EGF) depending on the cell type. Activated EGF-receptors lead 
to Shc/Grb2/Sos complex formation via their connected G-proteins. This adaptor-protein 
complex then activates the monomeric GTP-binding protein, Ras. Ras-GTP interacts with 
Raf-1 and thus activates kinases of the mitogen-activated protein kinase family, such as 
MEK-1, MEK-2 and PI3K. Other kinases, such as ERK1, ERK2 and Akt (protein kinase B) 
are activated downstream of these MAP kinase cascades and in turn activate transcription 
factors that are responsible for the cellular effects. One of these transcription factors is 
NF-kB. Ang II induces the phosphorylation of NF-kB through RhoA activation. Rho is 
another monomeric G-protein activated by a tyrosine kinase downstream of AT1R 
stimulation. NF-kB activation subsequently induces cytokine (IL-6, IL-8) and adhesion 
molecule (ICAM-1, VCAM-1) expression and secretion in vascular endothelial cells. This 
suggests that the Rho/ROCK (Rho kinase) pathway has a critical role in the Ang II-
induced progression of vascular inflammation (see also Figure 5) 9. A third monomeric G-
protein is activated by Ang II, called Rac. Rac is an important component of the NADPH 
oxidase complex, which in turn produces ROS and is also implicated in pathways 
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activating c-Jun N-terminal kinases (JNK). JNK are stress-activated phopho-kinases and 
have been shown to be indispensable for VSMC migration stimulated by Ang II.  
Interestingly, experiments with AT1 receptor point mutants suggest that the 
activation of MAP kinase and the formation of the second messengers IP3 and DAG can 
occur independently through ligand-selective stabilisation of different active states of the 
receptor 10. 
Endothelial AT1 receptor signalling has been suggested to play a major role in 
regulating the balance between nitric oxide (NO) and ROS in endothelial cells. NADPH 
oxidase is a multisubunit enzyme, similar to the neutrophil oxidases that are present in 
vascular cells, kidney cells, and cells of the central nervous system. Several animal 
models of experimental hypertension show Nox-enzyme dependent ROS production. Ang 
II activates NADPH oxidase, and the O2.-  that is subsequently produced, inhibits the 
endogenous vasodilator NO. Thereby vasoconstriction is promoted, increasing systemic 
vascular resistance and elevating the blood pressure. Moreover, O2.-  and related ROS 
might increase renal sodium re-absorption, which would also contribute to hypertension. In 
addition to its hypertensive effects Ang II also directly promotes inflammation and the 
development of atherosclerosis. Inflammation occurs through activation of T lymphocytes 
by Ang II in an NADPH oxidase dependent way. This was shown by abolishing the 
proliferative effect of Ang II on T cells with the NADPH oxidase inhibitor apocynin 11.  
The C-terminal cytoplasmic domain of the AT1 receptor might be functionally 
important for AT1 receptor signalling, desensitisation and receptor internalisation. It 
associates with non-G-protein signalling molecules and provides a binding site to form 
homo- and hetero-dimers of the AT1 receptor. Two AT1 receptor associated proteins have 
been identified to show contrary effects on AT1R signalling upon receptor binding. ATRAP 
(AT1-receptor associated protein) is thought to function as a negative regulator by 
potentiating AT1 receptor internalisation. Whereas, ARAP1 (type 1 Ang II receptor 
associated protein 1) might promote AT1 receptor recycling to the plasma membrane. An 
ARAP1 overexpressing mouse model suffers from hypertension 9.  
Structural analysis of the peptide hormone Ang II by Aumelas and his group in 
1985 revealed that the binding of Ang II and related peptides to receptors requires well-
defined conformational and dynamical properties of the tyrosine-4 and histidine-6 side 
chains. Peptides with high agonist activity require the presence of both the phenyl ring and 
the free carboxyl group at the COOH terminus. However, it seems that the large aromatic 
residue at position 8 is not directly involved in receptor binding, but mostly the carboxyl 
group. This has been concluded, because the biological activity of AT1R agonists is 
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greatly reduced or destroyed when the carboxyl group is amydated, when its configuration 
within the peptide is changed or when its position is shifted (such as in Ang I). 
Modifications in the side chain of the amino acid at position 8, may only affect the 
orientation of the histidine and tyrosine side chains that are thought to interact with the 
receptor 12.  
1.4. Treatment of hypertension by targeting the RAS 
Several drugs are currently available on the market to treat hypertension, including 
different kinds of diuretics, β-blockers, Ca2+-channel blockers and small molecule 
inhibitors of diverse components of the RAS. Diuretics reverse the reuptake of salt and 
water from the urine induced by Ang II in the kidney and thereby also reduce blood 
pressure. β-blocker act antihypertensive on the sympathetic nervous system that controls 
heart functions. Ca2+ channel blockers reduce the influx of Ca2+ and thereby cause 
vasodilatation. Pharmaceuticals against hypertension that target the RAS encompass 
renin blockers, ACE inhibitors, angiotensin II receptor blockers (ARBs) and prorenin 
receptor blockers. ACE inhibitors bind the active site of ACE, thus interfering with the 
ability of the enzyme to bind and cleave its substrates. Characteristic side effects of ACE 
inhibitors are dry cough and angioneurotic oedema. ARBs specifically block the 
vasoconstrictor effects of Ang II by blocking the binding of angiotensin II to the AT1 
receptor.  
Although, there is a variety of drugs available, antihypertensive treatment is still 
inadequately handled. 30% of patients with hypertension are still unaware of the danger of 
their condition. This is mainly due to the asymptomatic nature of hypertension. Effective 
treatment requires the motivation of the patient to continue daily drug intake over a long 
period of time. Because of the vast variety of risk factors and diseases like diabetes or 
metabolic syndrome that act on high blood pressure conditions, individual diagnosis and 
prescription of treatments is necessary. Furthermore, two or more medications are 
generally needed to achieve the goal blood pressure 3. Thus in addition to inadequate 
treatment, key factors affecting patient’s adherence to treatment, such as the presence of 
side-effects and concerns over taking long-term medication in the absence of symptoms 
are major reason for the high percentage of patients with arterial hypertension 13. 
1.5. Vaccination approaches to target the RAS 
Active immunisation inducing a specific immune response to components of the 
RAS could simplify antihypertensive treatments. One of the advantages of vaccination 
over the daily administration of small molecular drugs is that antibodies circulate in the 
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blood for a longer time span, resulting in a continuous blockade of angiotensin II. Current 
medications, in contrast, exhibit variations in activity, according to their way of 
administration that are not ideal for the treatment of a chronic condition, such as 
hypertension 14. Ideally a long lasting effect would be achieved with a few injections per 
year. The ease of this antihypertensive vaccination therapy should encourage better 
adherence to treatment 13. Furthermore, hypertensive immunotherapy would reduce drug 
interactions associated with conventional drug polypharmacy 15. However, the success of 
an anti-hypertensive immunotherapy requires the identification of an appropriate target for 
vaccination, the debarment of the danger of autoimmune damage and the possibility to 
induce sufficiently large amounts of antibodies.  
Facts that speak against the development of a vaccine against a self-antigen 
involve the inadequate knowledge about the effects of overstimulation of the immune 
system and the development of autoimmune diseases. Joël Ménard states in his review “A 
vaccine for hypertension” that high blood pressure is no longer a devastating disorder but 
a manageable risk factor. Pharmacological treatment of hypertension is widely available, 
safe and well-tolerated. Thus, the call for a vaccine targeting the RAS might not be 
justified. Furthermore, Ménard criticises that there are no data from long-term animal 
studies available that address the effects of a RAS vaccine in salt and water restrictive 
conditions. In his opinion, the vaccines, developed to treat hypertension so far, are applied 
in humans too rapidly and thus expose volunteers participating in clinical trials to an 
unacceptable risk. The booming research on vaccines targeting the RAS and other 
endogenous systems should thus rather be used to generate a better understanding of the 
structure and function of these systems and the complexity of immune responses involved 
in vaccination 16.  
The first attempts to actively immunize against components of the RAS were 
performed by Harry Goldblatt in 1951, using renin as the main target. Renin catalyses the 
processing of angiotensinogen and thus presents the initial and rate-limiting step in the 
RAS cascade. Immunization against renin achieved complete inhibition of endogenous 
plasma renin activity and decrease of blood pressure. However, this attempt has been 
stopped, because the induced immune reaction caused an organ-specific autoimmune 
disease in the kidney.  
Several other attempts to treat hypertension by vaccination used exogenous or 
endogenous antibodies raised against the different proteins and peptides of the RAS. 
Angiotensin converting enzyme was thought to present an attractive target for vaccination, 
because it is expressed on the endothelial surface and thus is directly exposed to 
circulating antibodies. On one hand, passive transfer of antibodies raised in rabbits 
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caused severe autoimmune reactions and death of the vaccinated rabbits. In rats, on the 
other hand, the same antibodies were able to limit the pressor effect of Ang II and led to a 
normalization of blood pressure within 24h. Active immunisation of rats with rabbit ACE 
induced a high specific antibody titre, but was lethal to the animals.  
The first approaches to target Ang I or Ang II by active vaccination did not show 
any effect on the blood pressure (Michel et al., 1989). This could be related to the low 
affinity of induced antibodies for the peptide or the generation of angiotensin in tissues 
inaccessible to antibodies. Peptides such as angiotensin are too small for active 
immunisation and thus have to be coupled to an immunogenic protein carrier 17.  
Recently, the potential of Ang I and II to mount antigen-specific and therapeutically 
effective immune responses against hypertension was re-investigated by several studies. 
In these approaches the angiotensins were chemically linked to different protein carriers 
like tetanus toxoid (TT), keyhole limpet haemocyanin (KLH) or diphtheria toxin (DT) and 
administrated together with aluminium hydroxide (Alum) or other adjuvants. Rats treated 
with an Ang I-TT conjugate vaccine, showed a significant reduction in the pressor 
response, when challenged with exogenous Ang I, but not with Ang II. These blood-
pressure lowering effects were comparable to those of Angiotensin II type I receptor 
antagonists (valsartan and frusemide). Although the vaccination with Ang I-TT led to the 
induction of a high antigen-specific humoral immune response in both experimental 
animals and healthy human volunteers, the effects on blood pressure could not be seen in 
humans 15. This finding was further confirmed in a study by Brown and his group with 
hypertensive patients who received a 12 amino acid analogue of Ang I covalently linked to 
KLH and adsorbed to Alum (referred to as PMD3117). The treatment regimen applied in 
this study was well tolerated and induced antigen-specific antibodies with a half-life of 
about 100 days. Additionally, PMD3117 vaccination induced changes in renin and 
aldosterone levels, proving its effect on the RAS. However, vaccination with PMD3117 
could not influence the blood pressure of patients compared to the placebo control group 
18
.  However, a different formulation of this Ang I vaccine which was developed by 
Protherics 19 and replaced Alum by a new adjuvant, namely Co Vaccine HTTM did show an 
effect on blood pressure in human healthy volunteers (Figure 6) and also resulted in a 10-
fold higher antibody response.  
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Immunization against AT1 receptor is in general complex, because antibodies must 
act in an antagonistic fashion to block its action. Most anti-AT1R antibodies have been 
found to act agonist-like 20. Furthermore, the accumulation of antibodies on cell surfaces 
may attract other components of the immune system such as complement system 
components and can therefore lead to autoimmune reactions. However, a study in young 
spontaneously hypertensive rats (SHR) immunised against a N-terminal peptide (residues 
14- 23) of AT1R conjugated with bovine gamma globulin (BGG) suspended in Freud’s 
adjuvant found that the development of genetic hypertension could be attenuated in this 
animal model. When administered intracerebroventricularly, antibodies against the same 
sequence of AT1R were shown to antagonise Ang II induced increase of blood pressure. 
Furthermore, these antibodies also prevented the blood pressure increase in Wistar rats 
subjected to two-kidney, one-clip procedure. In the early phase of this procedure, 
circulating Ang II levels are significantly increased. These results might indicate that the 
antibody competed with circulating Ang II for AT1R binding or that the AT1R is inactivated 
by internalisation upon antibody binding.21 In another study, SHR were vaccinated against 
a peptide of the extracellular portion of AT1R coded ATR12181 conjugated to TT and 
administered with Freud’s adjuvant. Vaccination induced humoral immune responses 
against peptide ATR12181 as demonstrated by Enzyme-linked immunosorbent assay 
(ELISA). Furthermore, a significant decrease of blood pressure was observed in the 
vaccinated group. ATR12181 also significantly attenuated the advance of kidney damages 
in hypertension. Fibrosis was clearly evident in control rats, but was rarely seen in the 
ATR12181- vaccinated group.  Moreover, any signs of autoimmune damage were not 
found by microscopic investigation 22.  
Figure 6: Results of the Proterics study: 18h blood pressure measurements of 
vaccinated and unvaccinated healthy human volunteers 
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Other approaches to induce antibodies that are able to block the RAS use Ang II 
as a target. Vaccination with Ang II derived peptides coupled to virus-like particles (VLP) 
led to the induction of a high anti-Ang II specific humoral immune response. More 
importantly, these high antibody titres correlated with a statistically significant reduction of 
blood pressure in SHR. Based on the knowledge that residues 2, 4 and 8 of the Ang II 
peptide are involved in its interaction with the AT1 receptor, a vaccine was designed to 
induce antibodies that specifically recognise Ang II. To achieve this, a modified Ang II 
peptide was conjugated via its N-terminus to the virus like particle Qβ. The resulting 
vaccine is called AngQb. Vaccination of mice with AngQb generated antibodies specific 
for the carboxy terminus of Ang II, which differs from Ang I and angiotensinogen. AngQb 
was first tested in mice and its high immunogenicity was further confirmed in rats. 
Inclusion of Alum, as a mild adjuvant, further increased antibody titres twofold. The 
antibodies evoked by AngQb were tested for their ability to bind Ang I, Ang II, Ang (2-8) 
and angiotensinogen. Ang II and Ang (2-8) were most strongly bound, followed by Ang I 
an order of a magnitude lower. Angiotensinogen could not be recognised with these 
antibody concentrations 14. 
 
 
Based on these promising results Cytos Biotechnology AG started a combined 
phase I/IIa study 23. Here, it could be demonstrated that the vaccine, referred to as 
CYT006-AngQb, showed no immune complex deposition, was well tolerated and induced 
a 100% responder rate. This means that vaccination with CYT006-AngQb does not induce 
severe side-effects and is safe to use. Treatment of hypertensive patients induced a 
strong and long lasting antibody response and led to a significant reduction of blood 
pressure in the early morning hours (Figure 7). However, in a second approach differing 
Figure 7: Results from the Cytos study: 24h blood pressure measurement in 
vaccinated and unvaccinated subjects 
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only in the vaccination schedule, these data could not be confirmed. Although a higher 
titre against Ang II was reached in vaccinated subjects, the blood pressure reduction was 
not significant.  
This diploma thesis is part of a project by AFFiRiS AG that aims at the 
development of a peptide vaccine targeting Ang II. Peptide-based vaccines use short 
sequences that have low immunogenicity and place a lower risk of inflammation side 
effects. Therefore, it is not necessary to break self-tolerance, mild adjuvants suffice for 
efficient vaccination and the risk of autoimmune disease is decreased.  
Furthermore, the right selection will create a peptide variant that is different from 
the target, enough to be recognised as foreign, but similar enough to induce a specific 
immune reaction. Choosing the right peptide variant enables a vaccine to elicit not only a 
very specific, but also the right kind (humoral, cellular, cytotoxic, regulative, …) of immune 
response. Here, the aim is to elicit a humoral response, but with the possibility to induce a 
long-lasting memory effect via T helper cell activation. This project should identify peptide 
variants that induce antibodies with an Ang II specific reactivity that excludes Ang I and 
Ang (1-7), and peptide variants that induce an antibody profile, that is similar to the one 
induced by the Ang II peptide. The peptide variants described here do not only share 
common epitopes with the angiotensin II octapeptide but also have high sequence 
similarities. Therefore, these peptides will be called Ang II-derived peptide variants or 
Variotope®s. 
This novel peptide-based vaccine approach will be developed for the treatment of 
hypertension and pathological conditions associated with the renin-angiotensin-system. 
For this purpose AFFiRiS AG selected Ang II-derived peptide variants using in house 
technologies. These peptides are chemically linked to different protein carriers like tetanus 
toxoid (TT) or keyhole limped haemocyanin (KLH) and administrated together with Alum 
as adjuvant. KLH from Megathura crenulata was chosen mostly because it is not a 
common immunogen in man, like TT. The use of common immunogens as peptide 
carriers is limited because of the risk of epitopic suppression. Epitopic suppression is due 
to antigenic competition between an existing population of carrier specific B-cell clones, 
and the newly forming population of peptide-specific B-cell clones. This means, that a 
subject that has been previously exposed to a specific carrier compound will boost the 
proliferation of already existing B-cell clones, rather than inducing the activation of new B-
cell clones specific for the peptide variant 15.  
Variotope® induced sera from animal experiments will be tested for antibody titres, 
reactivity to the Ang II sequence, specificity for this sequence (compared to Ang I, Ang 1-
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7), affinity for Ang II and its derivatives, efficacy in vitro and in vivo, half-life and safety. In 
this diploma thesis, the selectivity of Ang II-derived peptide induced antibodies will be 
analysed and their efficiency in blocking Ang II activity in vitro will be determined. 
Therefore, Variotope®-induced sera will be compared with Ang II peptide-induced sera in 
ELISA-experiments. Furthermore, a cellular assay to determine the activity of Ang II 
signalling and to evaluate the inhibitory capacitiy of Variotope®-induced sera on Ang II 
signalling will be established. This assay could be used to determine the potential 
correlation between antibody titre, affinity and functionality. Furthermore, this assay could 
be used to give preliminary data that will form the basis for proof-of-concept studies in 
spontaneously hypertensive rats. Thus, it provides an additional, cheaper and easier 
method to establish the functionality of sera.  
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2. Materials & Methods 
2.1. Specificity and selectivity 
2.1.1. BSA/KLH-activation 
100mg GMBS (N-[g-
Maleimidobutyryloxy]succinimide ester; Flucar) are 
solubilised in 1ml DMSO. 2.5ml of KLH (5.9mg/ml) or 
BSA (1:10 from 300mg/ml stock) are added to each 
0.1ml GMBS in DMSO. This mix is let to react for 30 
minutes at 25°C on a shaker (500rpm). Then, the 
mixture is centrifuged for 10 minutes at 8000rpm at 4°C to remove any precipitate. To 
remove unbound crosslinker the supernatant is purified via PD10 columns (2.5ml/ 
column). After discarding the first 3ml of flow through, 2.5ml of eluate are collected. The 
activated-carrier protein solutions are pooled and stored in appropriate aliquots at -80°C. 
PD10 columns are washed with 25ml of PBS and stored with 0.1% Na-Azide at 4°C. The 
columns can be reused 3-4 times.  
The capacity of activated carrier protein is determined by coupling it to a standard 
peptide. This standard peptide is solubilised at 10mg/ml in 0.2M Na-Phosphat buffer pH 
6.8. Different amounts of peptide solution are added to activated BSA (10:1) or activated 
KLH (2:1). The solutions are let to react for 2h at RT on a shaker. Free SH-groups on 
uncoupled cysteines are determined by Ellmann Assay: 15µl of each peptide sample are 
applied to a 96well plate, mixed with 100µl of Ellmann reagent (5,5’-Dithiobis(2-
nitrobenzoic acid); Sigma) and the OD at 412nm is measured.  
KLH: Sigma; 5.9mg/ml 
BSA: Roth; 69g/mol; 8076.3 
GMBS: Fluka; 280.24g/mol; CAS 80307-12-6 
2.1.2. BSA -coupling  
The desired peptide is diluted in 0.2M Na-Phosphate buffer pH 6.8 to give a 
500µM peptide solution. 10% DMSO are used to solubilise the peptide if necessary. A t0 
sample of the peptide solution is taken before addition of activated BSA. Then, 10% 
activated BSA is added to the dissolved peptide. The solution is let to react for 2h at RT 
on a shaker. The efficiency of the coupling reaction is tested by Ellmann Assay.  
Figure 8: GMBS 
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2.1.3. ABTS 
500mg of ABTS (2,2’- Aznobis-(3-ethylbenzthiazolin-6-sulfonic acid)) are dissolved 
in 1333ml of 0.1M citric acid. The pH is adjusted to 4.3 with 10M NaOH. Appropriate 
aliquots are stored at -20°C.  
ABTS: AppliChem; 548.69g/mol; CAS 30931-67-0 
2.1.4. Enzyme linked immunosorbent assay (ELISA) 
ELISA methods are generally used as analytic and diagnostic tools to detect the 
presence of antigens or antibodies in a sample. This is based on the binding activity of 
antibodies to their antigens that is detected via a conjugated enzyme-based colour 
reaction. 
ELISA (Nunc, Maxisorp) plates are coated with 50µl/ well of coating agent 
(antigen) at the appropriate concentration (1µM) in coating buffer (0.1M NaHCO3, pH 9.2-
9.4) and incubated over night at 4°C or for 1h at 3 7°C. Unbound coating agent is removed 
by discarding the supernatant. Free binding sites on the plates are blocked by incubation 
for 1h at 37°C with 100µl/ well blocking buffer (1x PBS, 1%BSA). Blocking solution is 
discarded and 50µl/well diluted sera are added. The titration steps start at a 1:100 fold 
dilution and continue 1:2 up to a dilution of 1:204800. Sera are diluted with dilution buffer 
(1xPBS, 0.1%BSA, 0.1%Tween20). The plates are then incubated for 1h at 37°C. 
Samples are discarded and plates are washed 3 times with washing buffer (1xPBS, 
0.1%Tween20). Then, the plates are incubated with 50µl/ well detection antibody (anti-mu 
IgG (H+L) biotinylated; Southern Biotech.; 1:1000) for 1h at 37°C. After another three 
washing steps, 50µl/ well Streptavidin-horse radish peroxidase (Roche) is added. The 
plates are incubated for 30 minutes at 37°C. The su pernatant is fully discarded and the 
plates are washed 3 times thoroughly. H2O2 is diluted 1:1000 fold in ABTS substrate 
solution (0.68mM ABTS in 0.1M Citric acid pH 4.3). 50µl/ well of this substrate solution is 
added and the plates are incubated for another 30 minutes at RT. The reactivity of sera 
with the antigen is determined by measuring the OD at 405nm. 
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2.2. Cellular Assay 
2.2.1. Cell culture  
HEK293 (human embryonic kidney) cells are grown in DMEM (Dulbecco´s 
modified Eagles Medium; Gibco) +Glutamax supplemented with 10% FCS (fetal calf 
serum; Gibco) and a Penicillin/ Streptavidin antibiotic mix. HEK293 cells may be held in 
culture for several months. 
HUVEC (human umbilical vein endothelial cells) are grown in basal Medium M200 
(Cascade Biologics), 2% FCS, 10ng/ml endothelial growth factor (EGF)/ 10µg/ml Heparin 
and 3ng/ml fibroblast growth factor (FGF) (Low Serum Growth Supplement kit, Cascade 
Biologics) in 0.25% gelatine coated flasks. HUVEC are primary cells and thus have a 
limited number of cell cycles. Therefore, HUVEC can only be kept in culture for 2-4 weeks.  
The cell number is determined using a light microscope. 0.4% (w/v) trypan blue 
(Sigma) is added to discriminate between live and dead cells (trypan blue is able to 
permeate only dead cells). The number of cells per millilitre solution is given by following 
equation:  
 
The percentage of viability of total cells in the solution is calculated as follows: 
 
2.2.2. Cellular ELISA  
15 000 cells/well are seeded in 200µl/well in 96 well plates and incubated over the 
weekend. On Monday afternoon, the cells are starved by changing the medium to 
0.25%FCS. On Tuesday, cells are stimulated at different time points (2-24h) with different 
concentrations of Ang II and TNFα respectively. The supernatant is collected and stored 
for detection of soluble ICAM-1 and secreted IL-8. The cells are then fixed with 4% ice 
cold methanol for 10 minutes and blocked with 5%BSA in 1%PBS (no Tween!). Detection 
of membrane bound ICAM-1 and VCAM-1 is done with biotinylated ICAM-1 and VCAM-1 
antibodies respectively. The detection procedure is the same as for normal ELISA 
(described in 2.1.4.).  
anti- VCAM-1: Chemicon International; CBL206; 0.1mg/ml 
mAb IgG1 anti- ICAM-1: R & D Systems; 11c8; 0.1mg/ml 
cells/ ml =  
unstained cells 
number of counted squares 
. 104 
unstained cells + blue cells 
100% -  100 . blue cells  viability [%] =  
2. Materials & Methods   
 
19
 
2.2.3. Transformation of E.coli DH5α  
Transformation describes the process in which DNA is transferred into a bacterial 
host strain. Aliquots of transformation ready bacterial cells (DH5α; Invitrogen) are thawed 
and incubated with 1-10µg of plasmid for 20 minutes on ice. The cells are thermally 
stressed by heating the cell solution to 42°C for 4 5sec. Then, the cells are incubated in 
1ml lysogeny broth (LB) medium (LB-Medium Lennox; Carl Roth GmbH; Nr. X964.1) for 1-
2h at 37°C to recover from this heat-shock. This re covery period allows the cells to 
produce resistance factors encoded by the plasmid. 100-200µl of the cell solution are 
plated on selective (containing antibiotics, such as Ampicillin (50µg/ml) or Kanamycin 
(30µg/ml)) LB plates (LB-Agar Lennox; Carl Roth GmbH; Nr. X965.1) and incubated at 
37°C o/n. One colony is selected for a 4ml precultu re and incubated for 8h at 37°C in 
selective medium. This preculture is then diluted 1:10 in 25ml (for Midiprep) or 100ml (for 
Maxiprep) selective LB and grown over night. Plasmid DNA is extracted according to 
QIAgen midi/maxi prep kit protocol. The quality of the DNA is analysed via agarose gel 
analysis and the quantity of DNA is determined by measuring the absorbance at 260nm. 
Using following equation, the concentration of DNA is calculated: c[DNA, µg/ml]= A260 · 
50µg/ml · dilution factor 
2.2.4. PCR (Polymerase chain reaction) 
Primer for excising the AT1R cDNA variant 2 from its original expression vector 
(pCMV6-XL4, Origene): 
Forward: 5’-AAAGAATTCATGATTCTCAACTCTTCTACTG-3’ 
Reverse: 5’-ATATGGATCCTCAACCTCAAAACATGGTGC-3’ 
Underlined sequences are recognition sites of restriction enzymes introduced for 
ligation into multiple cloning sites of other vectors (forward: EcoRI; reverse: BamHI). Red 
highlighted sequences are start- and end-codon of the AGTR1 gene (the stop codon is 
eliminated, because the PCR product is used to produce a fusion protein).  
The high fidelity polymerase (Roche) exponentially amplifies linear DNA strands, 
initiated by forward and reverse primers that are complementary to a specific part of the 
template DNA. Following tables describe the composition of the PCR-solution and the 
PCR thermo-cycler program. The PCR products are purified using QIAquick PCR 
purification kit. 
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Reaction Mix: 
10x PCR buffer containing 15mM MgCl2 5µl 
10mM dNTP Mix 1µl 
Forward and reverse primer (3µM stock) 5µl each 
DNA template 1-100ng 
H2O Up to 50µl 
high fidelity polymerase (Roche) 0.75µl (=2.6U) 
PCR program:  
94°C 2 minutes. 
initial 
denaturation 
94°C 15sec. 
55°C 30sec. 
72°C 90sec. 
30cycles 
72°C 7 minutes final elongation 
4°C ∞ storage 
2.2.5. Agarose gel electrophoresis 
1.2% agarose in 1x TAE (1L 50x stock: 242g Tris Base, 57.1 ml acetic acid, 100ml 
0.5M EDTA) is melted in the microwave oven. 5µl (1:10 000) Sybr safe DNA stain 
(Invitrogen) is added and the gel is casted. DNA samples are loaded, supplied with 5x 
loading dye (Fermentas). The GeneRulerTM 1kb DNA Ladder from Fermentas is used to 
estimate the size of the DNA bands (see Figure 9). The gel is run for approximately 30 
minutes at 90V in 1x TAE. The resulting bands are evaluated using UV light 
(Transilluminator M-26, bio Doc-It System). 
  
Figure 9: GeneRulerTM 1kb 
DNA Ladder (Fermentas) 
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2.2.6. Enzymatic digest 
Approximately 1µg DNA is incubated with 1µl of each Enzyme (EcoRI, BamHI; 
both obtained from Fermentas) in reaction buffer (2x TangoTM or 1x BamHI Buffer; 
Fermentas) for 1- 5h at 37°C. After the digest, sam ples are loaded on a 1.2% agarose gel 
and run for approximately 45  minutes at 100V. Samples are extracted from the gel and 
purified using QIAquick gel extraction kit.  
2.2.7. Ligation 
The T4 ligase catalyses the generation of phosphodiester bonds between two 
linear strands of DNA, such as between a vector and an insert. Appropriate amounts of 
vector (pEGFP-N1) and insert (AT1R cDNA PCR product) are ligated with 1µl T4 ligase 
(Fermentas) in 1x reaction buffer (10x Ligation Buffer: 400mM Tris-HCl, 100mM MgCl2, 
100mM DDT, 5mM ATP, pH 7.8; Fermentas). The reaction is conducted using a 
thermocycler programmed to keep 22°C for 1 hour, th en heat the sample to 65°C for 10  
minutes to inactivate the enzyme and then store the sample at 4°C until used. Ligated 
plasmids are transformed into E.coli DH5α (Invitrogen) and grown on selective LB plates 
(30µg/ml Kanamycin). Transformed E.coli cells are stored at -80°C in 15% glycerol. The 
plasmid is isolated using QIAquick Midi/ Maxi plasmid DNA precipitation kit protocol and 
send to Microsynth AG for sequencing. 
Sequencing primers: 
  AT1R-fw2:  5’-AATGTCGTAACAACTCCGCC-3’ 
  AT1R-fw3:  5’-TGGCTATTGTTCACCCAATG-3’ 
  AT1R-fw4:  5’-AAAAGATATTTTCTCCAGCTTCTAAA-3’ 
  AT1R-fw5:  5’-TATATCATGGCCGACAAGCA-3’ 
  AT1R-rev2:  5’-CCACCAAGCTGTTTCCAAAT-3’ 
  AT1R-rev3:  5’-GAACTTCAGGGTCAGCTTGC-3’ 
  AT1R-rev4:  5’-CAAGTTAACAACAACAATTGCATTC-3’ 
2.2.8. Transfection of HEK293 
Transfection is the process in which DNA is transiently or stably transformed into 
eukaryotic cells, where it is expressed. For the transfection, 1·106 cells/well are seeded on 
6-well plates and incubated over night. Then, full DMEM medium is changed to DMEM+ 
Glutamax without FCS or Pen/Strep. 
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Two different transfection methods were tested: 
2.2.8.1. Calcium Phosphate: 1- 4µg DNA are diluted in H2O and 9µl/ well CaCl2 to 
give a total volume of 74µl. This solution is slowly droped into 71µl/ well HeBS buffer 
(280mM NaCl, 1.5mM Na2HPO4, 50mM Hepes (Sigma H-7006)) while continuously 
shaking the tube. The transfection mix is added dropwise to the cells. 4h after the 
transfection, 10% FCS is added to each well. Transfected cells can be harvested 24- 48h 
after transfection.  
2.2.8.2. Lipofectamine Reagent: 1µg DNA is diluted in 100µl medium. Then 10µl 
Plus Reagent are added and the solution is incubated for 15 minutes at room temperature 
(RT). 10µl Lipofectamine Reagent is diluted in 100µl medium and this solution is added to 
the preincubated DNA solution. The Lipofectamine/ DNA solution is incubated for another 
15 minutes at RT. The ready mixture is added dropwise to the cells and the plate is 
shaken softly. Thus transfected cells are incubated for 1- 2h and then FCS is added to 
gain a 10% FCS solution. Cells can be harvested 24- 48h after transfection. 
2.2.9. FACS (Fluorescence activated cell sorting) 
Flow cytometry is a technique for counting, examining, and sorting microscopic 
particles suspended in a stream of fluid. Within the instrument, a laser is directed onto a 
focused stream of fluid and a number of detectors are positioned at the point where this 
stream passes through the light beam. Each suspended particle scatters the light in a 
characteristic way and fluorescent chemicals within the particle or attached to it may be 
activated to emit light. With this method various types of information about the physical 
and chemical structure of each individual particle can be obtained. FSC (forward scatter) 
correlates with the cell volume and SSC (side scatter) depends on the inner complexity of 
the particle (i.e. shape of the nucleus, the amount and type of cytoplasmic granules or the 
membrane roughness). 
Transfected HEK293 cells are detached from the plates with 1x trypsin (Sigma) 
and then counted using trypanblue. 3·105- 5·105 cells are centrifuged for 2 minutes at 
1000rpm and resuspended in 1ml ice cold FACS buffer (1xPBS, 1% BSA, and 0.1% 
sodium azide) with 1:10000 7-AAD (dead/live staining). 7-AAD intercalates with DNA, 
which is only accessible in dead cells or cell debris. Cells are measured with the FACS 
machine (FACScan Flow Cytometer 65; Becton Dickinson GmbH) and analysed using 
CellQuestPro.  
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2.2.9.1. FACS staining: Transfected cells are washed with 1xPBS and detached 
from 6-well plates using cell-dissociation solution (Sigma). Then the cells are counted and 
split to give 3·105 cells/ staining on a V-shaped 96-well plate. Cells are kept on ice at all 
times. Cells are washed twice by spinning the solution for 2 minutes at 1000rpm and 
resuspending the pellet in 100µl ice cold FACS buffer. Unspecific IgG reactions are 
blocked by incubating the cells 10 minutes with 1.1µg/ml Affini Pure goat anti-rat IgG Fcγ 
fragment specific antibody (Dianova) on ice. After the first blocking step cells are 
centrifuged for 2 minutes at 1000rpm and the supernatant is discarded. Unspecific 
reactions of immunoglobulins, used for detection, to Fc-receptors are blocked by 
incubating the cells for 5 minutes with 1µg/ml Fc-block (BD Pharmigen; purified rat anti-
mouse CD16/CD32) on ice. Again the solution is centrifuged and the supernatant 
discarded. Then the pellet is resuspended in 100µl FACS buffer and incubated for 30 
minutes with the first antibody (anti-AT1R; Santa Cruz; 1:20). Cells are washed twice with 
FACS buffer and incubated 30 minutes with 10µg/ml secondary donkey anti-mouse PE-
conjugated antibody (F(ab')2 Fragment Donkey Anti-Mouse IgG (H+L); Jackson Immuno 
Research; 715-116-151) in the dark. Again, the cells are washed and the fluorescence is 
measured in the FACS machine.  
2.2.10. Western Blot 
HEK293 cells transfected and untransfected cells are lysed in RIPA buffer ( 50mM 
Tris pH7.4, 150mM NaCl, 1% Triton-X, 0.5% Sodium-Deoxychelate, 5mM EDTA) 
supplemented with a protease inhibitor cocktail tablet (complete mini easypack sample, 
Roche) for 20 minutes on ice. After centrifugation at 13000 rpm for 10 minutes at 4°C, the 
supernatant containing protein is collected. These lysates are prepared for gel 
electrophoresis by mixing them with 5x Sample Buffer (0.2M tris-HCl pH 6.8, 10% w/v 
SDS, 20% v/v Glycerol, 0.05% w/v Bromophenolblue and 10mM beta-mercapto-ethanol) 
and boiling them for 2- 3  minutes. at 95°C. The sa mples are loaded onto a SDS-
polyacrylamide gel consisting of a 10% acrylamide running gel (pH 8.8) and a 4% 
acrylamide stacking gel (pH6.4) and the gel is run in 1x Running Buffer (25mM Tris-HCl, 
200mM Glycine, 0.1% w/v SDS) for approximately 1h at 30mA. Proteins within the cell 
lysates separate according to their mass to charge rate. A prestained protein ladder (Page 
Ruler Plus; Fermentas) is applied to the gel to enable evaluation of signals obtained by 
either Coomassie staining or Immunoblotting (Western Blot) of the proteins. The proteins 
separated within the polyacrylamide gel are then blotted at 4°C for 1h at 80V or o/n at 30V 
onto a nitrocellulose membrane. Non-occupied protein binding sites on the membrane are 
blocked with 5%BSA or 5% milk in 1x TBST (Trizma HCl, NaCl, pH 7.6, 0.1% Tween20) 
for 1h at RT. Then the membrane is incubated for 2h at RT or o/n at 4°C in primary 
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antibody in blocking buffer binding to the protein of interest. After washing 3x 10 minutes 
with 1x TBST, the membrane is incubated for 45 minutes in secondary antibody in 
blocking buffer. The membrane is washed again 3 times for 10 minutes each. ECL colour 
solution (GE lifesciences) is applied and the membrane is exposed to the 
chemiluminescence-measuring machine for 5- 41 minutes. 
antibody distributor dilution blocking buffer 
1E10-1A9 sc-81671 Santa Cruz Biotechnology 1:200 5% BSA in 1x TBST 
TONI-1 sc-57036 Santa Cruz Biotechnology 1:200 5% milk in 1x TBST primary α-AT1R 
N-10 sc-1173 Santa Cruz Biotechnology 1:200 5% milk in 1x TBST 
primary α−β-Actin ab8227 Abcam 1:1000 5% milk in 1x TBST 
primary α-GFP ab6673 Abcam 1:500 5% milk in 1x TBST 
α-mouse 
115-035-068 Jackson 
Immunolab 1:20 000 5% milk in 1x TBST 
α-rabbit NA934V GE Healthcare 1:10 000 5% milk in 1x TBST secondary 
α-goat A5420 Sigma 1:2000 5% milk in 1x TBST 
2.2.10. Luciferase assay 
HEK293 cells are co-transfected with AT1R-EGFP fusion vector (2µg/ transfection) 
and NF-κB-luc (2µg/ transfection) expression vector on a 6 well plate or on 60cm2 Petri-
dishes. Approximately 20 hours after the transfection HEK293 cells are detached from the 
plate using enzyme free cell-dissociation solution (Sigma) and transferred onto a 96-well 
black VIEW plate (PerkinElmer). There the cells are starved in DMEM without FCS and 
stimulated with 10ng/ml or 5ng/ml TNFα and 10-9M – 10-5M Ang II for 24h. 10-4M losartan 
is added 4h before stimulation of cells with Ang II. Sera derived from immunisation of mice 
with different Ang II peptide variants or anti-Ang II control antibody (0500-0030 Serotec) 
are applied together with Ang II stimulation. After 24h of stimulation the cell culture 
supernatant is discarded and the cells are lysed with 100µl/ well Reaction Reagent 
(Bioassay Systems) containing lysis buffer and luciferase substrate. After 2  minutes, lysis 
is complete and the chemiluminescence is measured using the GenIOS reader with a gain 
of 150 and an integration time of 5000 milliseconds.  
2.2.11. Fluorescence Microscopy 
Different counts of transfected HEK293 cells are applied on adhesion slides 
(Marienfeld) and air dried for approximately 1h. Then one drop of warm mounting medium 
(DakoCytomation Glycergel) is added and the slide is covered with a cover slip. Cells are 
analysed immediately, because the mounting medium is lethal to unfixed cells. Pictures 
are taken using a fluorescent microscope (60x amplification using an immersol objective).  
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3. Results 
3.1. Specificity for Ang II examined via ELISA  
BALB/c mice and Wistar rats were used to test the immunogenicity of the Ang II 
octapeptide and Ang II derived peptide variants. These peptide variants contain several 
modifications compared to Ang II. These modifications include changes of chemical 
properties of the C-terminal end (C-term) or of the amino acid sequence of the peptide. 
The peptides used for immunisation of mice and rats were bound via their N-terminal end 
(N-term) to KLH as a carrier protein. An additional cysteine was added to the N-term of 
Ang II, Ang I, Ang (1-7) and the peptide variants to couple these peptides to the carrier 
protein. The conjugation to a large protein carrier such as KLH usually increases the 
immunogenicity of peptides. Furthermore, the C-term of these peptides conjugated to KLH 
is free to elicit an appropriate immune response. The Ang II C-term is thought to contain 
the major binding site to the AT1 receptor. Blockade of Ang II binding to the receptor by 
antibodies against this site thus might inhibit Ang II function. The peptide-carrier conjugate 
was formulated with aluminium hydroxide (Alum) and injected subcutaneously into BALB/c 
mice and Wistar rats. Twelve days after this prime immunisation, Serum1 was taken. Both 
animal models were boosted for three times in biweekly episodes. Sera2, 3 were taken 
twelve days after each boost. One week after the third boost, Serum 4 was taken. Another 
week after this last boost, the animals were sacrificed and Endsera were collected (see 
Figure 10).  
 
Figure 10: Vaccination Schedule 
At first the humoral immune response induced by immunisation of BALB/c mice 
with Ang II was characterised. For this purpose, total IgG levels against Ang II in mouse 
sera after immunisation with Ang II were determined by enzyme linked immunosorbent 
assay (ELISA). The IgG levels against Ang II in mouse sera after immunisation give 
information about the reactivity of the antibodies in these sera to Ang II. Furthermore, the 
crossreactivity of these sera generated against Ang II to Ang I, Ang (1-7) and 
angiotensinogen was also analysed by ELISA.  
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ELISA experiments are conducted using 1 to 2 dilution steps of each Serum 
starting with 1:100 down to 1:204800 in twelve steps. Antibody titres are defined as 
dilution factor at an OD value that equals half of the OD maximum. All titres shown here 
represent mean values of titres from five animals each. The titres against the original 
peptide in all graphs represent the mean value from all experiments (approximately 75 
mice). 
3.1.1. Epitope specificity of Ang II-induced sera changes after multiple vaccination 
steps 
The first experiment examined the anti-Ang II IgG response of BALB/c mice after 
immunisation with the Ang II-KLH conjugate vaccine. The immunogenicity of different sera 
(Serum1 to Endserum) of BALB/c mice immunised with Ang II is shown in Figure 11. Titres 
in Serum1 are very low compared to the other sera. However, the titres increase with 
each boost vaccination and are at the highest level in the Endserum. 
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Figure 11: Titres of Serum1 to Endserum of mice immunised with Ang II against Ang II; n = 
5; blue bars: Serum1, red bars: Serum2, yellow bars: Serum3, turquoise bars: Serum4, pur-
ple bars: Endserum 
Ang I and Ang 1-7 differ from Ang II only in their C-terminal end. Thus, an antibody 
induced against Ang II might also react with Ang I and Ang 1-7. The precursor protein 
angiotensinogen is abundantly present throughout the body and might have an additional, 
so far unknown function. Thus, it should not be recognised by antibodies against Ang II. 
Therefore, the crossreactivity of the same sera derived from Ang II immunisation of 
BALB/c mice to Ang I, Ang 1-7 and angiotensinogen was examined.  
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Figure 12: Titres of Serum1 to Endserum of mice immunised with Ang II to Ang II, Ang I, Ang 
(1-7) and angiotensinogen; n = 5; blue bars: Serum1, red bars: Serum2, yellow bars: Se-
rum3, turquoise bars: Serum4, purple bars: Endserum 
As shown in Figure 12 the overall immune response in Serum1 is low. However, in 
Serum3 to Endserum there are significant differences in the reactivity to Ang II and the 
crossreactivity to Ang I, Ang 1-7 and angiotensinogen. Ang I has two additional amino 
acids (histidine and leucine) at its C-term compared to Ang II. Thus, the peptide backbone 
is continued and the negative charge of the Ang II C-term is lost. In Serum2 the titre 
against Ang I is lower than the titre against Ang II. However, this changes with additional 
boost injections. In the Endserum, the crossreactivity to Ang I is even higher, than the 
reactivity to Ang II. Ang 1-7 consist of the first seven amino acids of Ang II without the 
phenylalanine residue at the very C-terminal end. The titre against Ang 1-7 in all sera is 
significantly lower than against the original peptide. In the Endserum the titre of antibodies 
against Ang 1-7 is about 40% of the titre of antibodies against Ang II. However, the 
greatest titre difference is seen in Serum2. Here, the level of IgG against Ang 1-7 is only 
about 5% of the IgG level against Ang II. The specificity of the antibodies in Serum2 
seems to depend on the eighth residue. These results indicate that the very C-terminal 
residue of Ang II might be important for antibody recognition. Angiotensinogen is not 
recognised from any antibodies in sera of mice immunised with Ang II. 
To further examine the specificity of antibodies induced by immunisation of mice 
with Ang II for the C-terminal end of the octapeptide, the crossreactivity to different 
peptide variants was examined. These peptide variants contain several modifications in 
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their amino acid sequence compared to Ang II. The three C-terminal amino acids of the 
Ang II octapeptide were exchanged to alanine, as a neutral amino acid (C-DRVYIAPF, C-
DRVYIHAF, C-DRVYIHPA). These peptides were used to test which residues of Ang II 
determine the specificity of antibodies against the Ang II C-term. An additional peptide 
completely lacks the C-terminal end (C-DRVYI). Another one only shares the three very 
C-terminal amino acids (C-DAAAAHPF) with the original Ang II sequence. This 
experiment should also examine whether sera taken after early immunisation steps 
(Serum1 and Serum2) show higher specificity for the Ang II C-terminal end, than sera 
taken after later immunisation steps (Sera3- Endserum). 
0
5000
10000
15000
20000
25000
30000
35000
40000
C-AngII
serum 1
serum 2
serum 3
serum 4
endserum
C-DRVYIHPF C-DRVYIHPF-
NH2
C-DRVYIAPF C-DRVYIHAF C-DRVYIHPA C-DAAAAHPF C-DRVYI
 
Figure 13: Titres of Serum1 to Endserum of mice immunised with Ang II; n = 5; blue bars: 
Serum1, red bars: Serum2, yellow bars: Serum3, turquoise bars: Serum4, purple bars: 
Endserum 
Figure 13 shows the development of titres of sera from mice immunized with the 
original Ang II octapeptide conjugated to KLH via an additional cysteine (C-DRVYIHPF) 
against several different Ang II derivatives.  
Here again, in Serum1 the overall immune response is lower than in following 
sera. Serum2 shows significant differences in antibody titres against the different peptides 
in the ELISA. The peptide C-DRVYIHPF-NH2 differs from Ang II only in the fact that its C-
terminal end is amydated. Thus, the negative charge of the terminal carboxy group is lost 
and an antibody recognising this charge would not bind. The titre of C-DRVYIHPF-NH2 
antibodies in Serum2 is significantly lower than the titre of antibodies against the original 
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peptide. However, later sera show a similar titre for C-DRVYIHPF-NH2 as for Ang II, thus 
the specificity for the negatively charged carboxyl-group might have changed. Peptide 
variants C-DRVYIAPF, C-DRVYIHAF and C-DRVYIHPA have mutations within the three 
C-terminal amino acids (HPF) of the Ang II octapeptide. ELISA data show, that the titres 
against C-DRVYIAPF and C-DRVYIHPA are about 50% reduced compared to the titres 
against Ang II. The greatest titre difference of antibodies to these test peptides compared 
to antibodies to Ang II is seen in Serum2. However, the titres against C-DRVYIHAF in 
Serum3 to Endserum are the same as the titres against the original peptide. Only in 
Serum2 there is a reduction to 20% of the titres against Ang II. This might indicated that 
the proline at position 7 is not important for antibodies binding the Ang II C-term. The 
peptide variant C-DAAAAHPF only shares the first and the last three C-terminal amino 
acids with the original Ang II sequence. Thus, this peptide variant is used to determine the 
titres of antibodies against the C-terminal end of Ang II in the different sera. In Serum1 
and Serum2 the crossreactivity to C-DAAAAHPF is reduced to 30% of the reactivity to 
Ang II. In later sera however, the titres increase and reach the same level as titres against 
Ang II. The peptide variant C-DRVYI completely lacks these last three C-terminal amino 
acids. Thus, the reaction of sera to this peptide variant should be low, if the C-term is 
recognised specifically. The titres against C-DRVYI of all sera are significantly reduced, 
compared to titres against Ang II. 
The relation of the reactivity to Ang II and the crossreactivity to Ang I, Ang 1-7, 
AGT and Ang II derived peptides within the different sera is summarised in Table 1. 
Table 1: Titres against Ang II derivatives as percentage of titres against the original peptide 
  
serum 1 serum 2 serum 3 serum 4 Endserum 
C-DRVYIHPF 100 100 100 100 100 
C-DRVYIHP 12 4 33 37 38 
C-DRVYIHPFHL 12 45 135 112 129 
C-DRVYIHPF-NH2 23 26 84 83 108 
Angiotensinogen 12 4 3 4 3 
C-DRVYIAPF 12 9 50 46 54 
C-DRVYIHAF 12 22 160 90 111 
C-DRVYIHPA 12 7 44 46 46 
C-DAAAAHPF 30 28 260 102 151 
C-DRVYI 15 14 56 21 45 
3.1.2. Assessment and selection of peptide variants 
The aim of the project is to generate different Ang II derived peptide variants and 
characterise their immunologic properties. The immunogenicity of these peptide variants, 
the reactivity of peptide-induced antibodies against Ang II and the crossreactivity of these 
antibodies to Ang I and Ang 1-7 were analyse by ELISA. These experiments should 
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examine whether the crossreactivity to Ang I and Ang 1-7 of sera from mice treated with 
different peptide variants can be varied by modifying the Ang II peptide. 
Ideal peptide variants or Variotope®s should have a high immunogenicity and 
induce sera that show high reactivity to Ang II. However, they should also induce sera that 
are specific for Ang II and show reduced crossreactivity to Ang I and Ang 1-7. 
Furthermore, Variotope®s should be able to induce a long lasting humoral response and 
lead to the development of memory cells. The specificity and duration of the immune 
response might also depend on the affinity of sera for Ang II and its derivatives. In the 
following experiments, the effects of mutations within the Ang II octapeptide on the 
specificity of peptide induced-sera for Ang II, Ang I and Ang 1-7 are analysed. 
3.1.2.1. Modifications with a neutral amino acid 
The previous experiment shows that the reactivity to Ang II of antibodies induced 
by immunisation with Ang II differs from the crossreactivity of these antibodies to peptides 
were single residues of the Ang II octapeptide are exchanged with a neutral amino acid. 
Thus, the specificity of mouse sera for Ang II, Ang I and Ang 1-7 might be varied by 
immunisation with peptide variants rather than with Ang II. The next experiment should 
examine whether immunisation of mice with peptides containing a neutral amino acid at 
two positions within the Ang II sequence changes the reactivity to Ang II and the 
crossreactivity to Ang I and Ang 1-7 in the serum.  
 
Figure 14: Titres against Ang II, Ang I and Ang 1-7 of Sera of mice immunised with Ang II-
derived peptides containing a neutral amino acid at two positions in the Ang II sequence; 
Endserum; n = 5; blue bars: Ang II, red bars: Ang I, yellow bars: Ang 1-7 
Figure 14 shows the titres of Endsera against Ang II (blue), Ang I (red) and Ang 1-7 
(yellow) of mice immunised with different Ang II-derived peptides containing two neutral 
amino acids. In most peptide variant-induced sera the reactivity to Ang II is lower than in 
sera of mice immunised with Ang II itself. However, three of the six peptide variants 
shown in Figure 14 (Ang II-029, Ang II-030 and Ang II-036) have the same or even a 
0
10000
20000
30000
40000
50000
60000
70000
80000
C-DRVYIHPF AngII-033AngII-032AngII-031AngII-036AngII-030AngII-029C-AngII
Peptides with double alanine exchanges
AngII: C-DRVYIHPF
AngI: C-DRVYIHPFHL
Ang1-7: C-DRVYIHP
3. Results   
 
31
 
higher immunogenicity than the original peptide (C-Ang II), displayed by a higher titre 
against Ang II. Sera evoked by immunisation with these peptides also recognise Ang I at 
the same or even a higher level as Ang II. However, the titres against Ang 1-7 are 
significantly lower in sera obtained by immunisation of mice with these Variotope®s than 
in sera induced by Ang II. In sera from mice immunised with Ang II-029 or Ang II-030, the 
titre against Ang 1-7 is only about 6-12% of the titre against Ang II. Ang II-029, Ang II-030 
and Ang II-036 all share modifications within the three central amino acids of the Ang II 
peptide (VYI). As soon as one of the last three C-terminal amino acids of the octapeptide 
is exchanged to a neutral amino acid, as it is the case in Ang II-032 and Ang II-033, the 
titres against all three angiotensin peptides (Ang II, Ang I, and Ang 1-7) align.  
The next experiment should examine whether the effects on the reactivity of 
antibodies induced with peptide variants, seen before, can be potentiated when the 
Variotope®s used for immunisation contain a neutral amino acid at three or four positions 
within the Ang II sequence.  
 
Figure 15: Titres against Ang II, Ang I and Ang 1-7 of Sera of mice immunised with Ang II-
derived peptides containing a neutral amino acid at three or four positions in the Ang II 
sequence; Endserum; n = 5 
Figure 15 shows the reactivity of sera to Ang II (blue), Ang I (red) and Ang 1-7 
(yellow) evoked by immunisation with Ang II-derived peptides containing a neutral amino 
acid at three or more positions within the Ang II peptide. Considering the experimental 
fluctuations of ELISA analysis, the titres of sera induced by most peptide variants shown 
in Figure 15 (Ang II-054, Ang II-066, Ang II-067) are as high as or higher than of sera 
induced by Ang II. Also, all peptide variants, except Ang II-055 where one of the three C-
terminal amino acids is changed to a neutral amino acid too, show a significant reduction 
to 3% -11% of the crossreactivity to Ang 1-7 compared to the Ang II immunised group. 
However, here, especially peptide variants Ang II-066 and Ang II-67 show also a 
significant reduction of the crossreactivity to Ang I to about 60% of Ang II-induced sera. 
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These peptide variants contain modifications within the three central amino acids of the 
Ang II peptide. As already seen in previous experiments, the crossreactivity to Ang 1-7 
seems to depend on the three C-terminal amino acids and the crossreactivity to Ang I 
seems to depend on the three central amino acids of Ang II.  
Mice are used as model organisms for a variety of pre-clinical studies. However, 
data derived from mouse experiments can not always be applied for other species, such 
as humans. To show that these results are not specific for mice, a similar experiment was 
done in rats and the rat sera were also analysed for their reactivity to Ang II and their 
crossreativity to Ang I and Ang 1-7 (Figure 16). This experiment should examine whether 
the results obtained in mice do also apply for another species.  
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Figure 16: Titres of Sera of rats immunised with Ang II-derived peptides with several alanine 
exchanges against Ang II, Ang I, Ang 1-7; Serum 4; n = 5 
In general, the immunogenicity of Ang II-peptide KLH conjugate vaccine is lower in 
rats than in mice. In contrast to mice, Ang 1-7 is better recognised by sera derived from 
rats immunised with Ang II. However, as already seen in mice, titres against Ang II are as 
high as or higher in most Variotope®-immunised groups compared to the Ang II-
immunised group. Peptide variants Ang II-036 and Ang II-030 show a high 
immunogenicity and antibodies-induced by these peptides have a significantly reduced 
crossreactivity to Ang 1-7. The IgG levels in Ang II-036 and Ang II-030 induced sera are 
about 17-50% of the titre against Ang II. Ang II-030 induced sera also show higher 
selectivity for Ang II, because here, the crossreactivity to Ang I is only 40% of the 
reactivity to Ang II.  
These data indicate that the results obtained in rats are comparable to the results 
obtained in mice. In both animals, immunisation with peptide variants containing 
modifications within the three central amino acids of the Ang II sequence change the 
crossreactivity of sera to Ang I compared to sera induced by Ang II itself.  
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3.1.2.2. Modifications with chemically distinct amino acids 
The chemical properties of the eight amino acids of Ang II might play a role for the 
conformation of the peptide and the recognition of the peptide by antibodies. By 
exchanging specific residues with amino acids of a different chemical constitution the 
conformation of the peptide and the recognition pattern of antibodies can be modified. For 
the next experiments, Variotope®s were produced that contain substitutions of specific 
residues of Ang II with amino acids with similar or contrary chemical properties to the 
original amino acid. These specific modifications were chosen based on preliminary data 
from previous experiments. It was examined whether the reactivity of peptide induced 
sera to Ang II and the crossreactivity to Ang I and Ang 1-7 can be modified by changing 
the chemical properties of the peptide used for immunisation. These experiments were 
conducted in BALB/c mice.  
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Figure 17: Titres of Sera of mice immunised with Ang II-derived peptides containing single 
amino acid exchanges on different positions within the octapeptide against Ang II, Ang I 
and Ang 1-7; Endserum; n = 5 
Figure 17 shows titres of sera induced by vaccination with peptides containing 
single amino acid substitutions. Again, immunisation of mice with most Variotope®s (Ang 
II-097, Ang II-102, Ang II-125, Ang II-126, Ang II-132) induces a higher titre against Ang II 
than immunisation with Ang II itself. Most peptide variants also show a significant 
reduction in the crossreactivity to Ang 1-7 (Ang II-080, Ang II-088, Ang II-097, Ang II-125, 
Ang II-126) and some even in the crossreactivity to Ang I (Ang II-080, Ang II-088, Ang II-
097, Ang II-126). The most dramatic change concerning the crossreactivity to Ang I can 
be seen in sera derived from immunisation with the peptide variant Ang II-097. However, 
there are also Variotope®s that, although different from the sequence of the original 
peptide, behave similar as the original peptide concerning the crossreactivity of induced 
sera to Ang I and Ang 1-7 (Ang II-076, Ang II-102, Ang II-132). The results from these 
experiments are summarised in Table 2. 
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Table 2: Crossreactivity of sera induced by Ang II-derived peptides containing single amino 
acid exchanges to Ang I and Ang 1-7 as the percentage of their reactivity to Ang II 
  
C-Ang II Ang II-080 Ang II-076 Ang II-125 Ang II-097 Ang II-102 Ang II-126 Ang II-132 Ang II-088 
Ang II 100 100 100 100 100 100 100 100 100 
Ang I 121 65 117 158 51 85 83 111 49 
Ang 1-7 33 11 22 19 12 23 9 43 28 
The next experiment should examine whether the effects on the reactivity of 
antibodies induced by Variotope®s containing single amino acid substitutions can be 
potentiated with Variotope®s containing amino acids with chemical properties that differ 
from the original amino acids at several positions within the Ang II sequence. 
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Figure 18: Titres of Sera of mice immunised with Ang II-derived peptides containing multiple 
amino acid exchanges against Ang II, Ang I and Ang 1-7; Serum 4; n = 5 
Figure 18 shows titres of sera induced by vaccination with Ang II-derived peptides 
containing multiple amino acid substitutions. All Variotope®s depicted here, show good 
immunogenicity against Ang II compared to sera induced by Ang II-immunisation. 
Furthermore, the crossreactivity of sera to Ang 1-7 induced by vaccination with any of 
these peptide variants is significantly reduced to as low as 1% of the reactivity to Ang II 
(Ang II- 193 and Ang II- 198). Moreover, also the crossreactivity to Ang I is reduced in 
most of these sera. In mouse sera induced by immunisation with Ang II- 192, Ang II- 193, 
Ang II- 198 the crossreactivity to Ang I is reduced to 40% of the reactivity to Ang II. These 
Variotope®s contain five modifications each and do only share two amino acids with the 
original Ang II sequence. The relation of the reactivity to Ang II and the crossreactivity to 
its derivatives within the different sera is further outlined in Table 3.  
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Table 3: Crossreactivity of sera induced by Ang II-derived peptides containing multiple 
amino acid exchanges to Ang I and Ang 1-7 as the percentage of their reactivity to Ang II 
 C-Ang II Ang II-173 Ang II-175 Ang II-177 Ang II-192 Ang II-193 Ang II-195 Ang II-198 
Ang II 100 100 100 100 100 100 100 100 
Ang I 121 64 62 80 44 36 70 37 
Ang 1-7 33 11 8 8 3 1 3 1 
The affinity of most sera described in these ELISA experiments was determined by 
competition ELISA after Friguet et al 1988 24 or using a Biacore machine. These data are 
not shown here. However, the affinity of sera for Ang I and Ang 1-7 is in general reduced, 
even if the titres against these angiotensin peptides are high. Interestingly only peptides 
that contain the three central amino acids of the Ang II sequence induce antibodies that 
show similar affinity for Ang II, Ang I and Ang 1-7 compared to sera induced by Ang II. 
Peptide variants that contain a neutral amino acid at one of the two C-terminal residues 
induce sera that show reduced affinity for Ang II and Ang I, whereas the affinity for Ang 1-
7 is increased compared to other peptide variant-induced sera. 
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3.2. Cellular assay (Functional Assays) 
A cellular assay should be established to determine the activity of Ang II and to 
evaluate the inhibitory capacitiy of Variotope®-induced sera on Ang II signalling. This 
assay will be used to analyse the potential correlation of titre and affinity of Variotope®-
induced antibodies and their functionality in blocking Ang II signalling. To establish a 
reliable in vitro assay for the determination of Ang II activity and for the evaluation of the 
inhibitory capacity of Variotope® induced sera, the signal measured after Ang II 
stimulation must differ significantly from the un-stimulated control. This would allow a 
comfortable margin to see effects of Variotope® induced sera on Ang II signalling. 
3.2.1. Cellular ELISA with HUVEC (human umbilical vein endothelial cells) 
Human umbilical vein endothelial cells possess functionally active angiotensin II 
and TNFα receptors. Stimulation via these receptors has been shown to up-regulate 
cellular adhesion molecules, such as ICAM-1 and VCAM-1 upon stimulation 25. The 
amount of ICAM-1 and VCAM-1 molecules expressed on the surface of stimulated 
HUVECs was determined via cell-based ELISA. The basic parameters for this assay have 
already been established and the assay was used in house with stimuli other than Ang II. 
Therefore, it was examined whether Ang II stimulation of HUVEC would give a 
measurable signal in ICAM-1- or VCAM-1- ELISA experiments. HUVEC cells were grown 
on a 96 well plate and stimulated with different concentrations of TNFα and Ang II for 
various lengths of time. TNFα was always used as a positive control. The ICAM-1 or 
VCAM-1 increase was measured using anti-ICAM-1 or anti-VCAM-1 antibodies on 
methanol fixed HUVECs. 
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Figure 19: Detection of cell surface ICAM-1 expression via cellular ELISA on fixed HUVECs 
after 2-8h stimulation with different concentrations of TNFα or Ang II; red: un-stimulated 
cells; yellow: un-stimulated with DMSO; pink and dark blue: TNFα positive controls; purple, 
brown, turquoise, dark and light blue: different concentrations of Ang II 
As shown in Figure 19, stimulation of HUVEC with 10ng/ml or 1ng/ml TNFα results 
in a significant increase of ICAM-1 (intracellular cell adhesion molecule) expression on the 
cell surface. Both concentrations of TNFα used in this experiment increase the ICAM-1 
signal continuously as a function of time. The maximum of ICAM-1 expression seems not 
to be reached after 8h of stimulation with either 10ng/ml or 1ng/ml TNFα. Ang II seems to 
increase ICAM-1 expression on the cell surface of HUVECs too. However, the ICAM-1 
signal is not increased significantly above negative control level. A negative control with 
10% DMSO is used, because the 10-3M Ang II stock solution contains 10% DMSO. There 
seems to be an effect of DMSO on ICAM-1 expression (yellow curve). However, the 
amount of DMSO is decreased in the Ang II solution with each dilution step and the de-
crease of ICAM-1 expression caused by DMSO is not significant. 
3. Results   
 
38
 
VCAM-1
0,0
0,1
0,2
0,3
0,4
0,5
2h 4h 6h 8h
O
D4
05
unstimulated DMSO 10ng/ml TNFα 1ng/ml TNFα 10-5M AngII
10-6M AngII 10-7M AngII 10-8M AngII 10-9M AngII
O
D4
05
 
Figure 20: Plasma-membrane bound VCAM-1 detection via ELISA on fixed HUVECs after 2-
8h stimulation with different concentrations of TNFα or Ang II; red: un-stimulated cells; 
yellow: un-stimulated with DMSO; pink and dark blue: TNFα positive controls; purple, 
brown, turquoise, dark and light blue: different concentrations of Ang II 
Figure 20 shows that stimulation of HUVEC with 10ng/ml or 1ng/ml TNFα results in 
a significant increase of VCAM-1 (vascular cell adhesion molecule) expression on the cell 
surface. Already after 4h the VCAM-1 signal, measured as the optical density at 405nm is 
doubled compared to the negative control (in red). The signal increase reaches a plateau 
after 6h of stimulation with 1ng/ml TNFα. The VCAM-1 expression induced by 10ng/ml 
TNFα might increase even after 8h of stimulation. However, stimulation of HUVECs with 
10-5- 10-9M Ang II did not result in a significant increase of surface bound ICAM-1 or 
VCAM-1. Although the assay was repeated several times and with different conditions, the 
ICAM-1 or VCAM-1 upregulation published by Pastore et al. in 2008 could not be 
reproduced here. Therefore, the cellular ELISA measuring ICAM-1 and VCAM-1 cell 
surface expression in HUVECs can not be used to determine Ang II signalling activity. 
It has been published that soluble ICAM-1 is also secreted by HUVECs upon 
stimulation with 10-6M Ang II 25. Therefore, the amount of ICAM-1 molecules in the cell-
culture supernatant from previous cell-based ELISA experiments was determined in the 
next set of experiments. For this purpose a commercially available sandwich ELISA kit for 
ICAM-1 (R&D Systems) was used. However, not even the positive control (TNFα 
stimulation) showed any signal increase when the assay was conducted according to the 
manufacturer’s instructions (see Figure 21). 
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Figure 21: Soluble ICAM-1 measured in supernatants of TNFα and Ang II stimulated HUVEC 
according to the ICAM-1 ELISA kit protocol and ICAM-1 standards provided with the ICAM-1 
ELISA kit (R&D Systems) 
 As shown in Figure 21, the ICAM-1 standards provided with the ICAM-1 ELISA kit 
show a signal according to the known concentration of ICAM-1 in each sample. However, 
none of the HUVEC supernatants induces a measurable signal no matter how the cells 
were stimulated. To determine the effect of the incubation procedure of the different 
components of the ICAM-1 ELISA kit, several incubation- steps and –times were tested. 
To analyse the effect of the cell culture medium the cell culture supernatants were spiked 
with 50ng ICAM-1 standard solution. Figure 22 shows significant fluctuations between 
these different procedures. 
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Figure 22: Evaluation of different procedures for detection of soluble ICAM-1 using a ready 
to use sandwich ELISA kit (R&D Systems) with cell culture supernatants of stimulated 
HUVECs spiked with 50ng ICAM-1 standard solution. Blue bars: 50µl supernatant was 
incubated for 1h on antibody coated plates before 50µl of conjugate were added directly to 
the supernatant. Yellow bars: The supernatant was discarded after the incubation period 
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and then the conjugated antibody was added to the plates. Red bars: Supernatant and 
antibody conjugate were added to the plates at the same time without prior incubation 
period. However, in all three procedures supernatant of DMSO treated cells spiked with 
50ng ICAM-1 standard shows a significantly lower signal that 50ng ICAM-1 standard alone. 
However, the supernatant of cells stimulated with 1ng/ml TNFα does not give any signal in 
either of these procedures. 
The results depicted in Figure 22 show that the presence of DMEM cell culture 
medium and DMSO in the cell culture supernatant decreases the signal measured with 
the ICAM-1 ELISA kit (R&D Systems). However, none of the procedures tested in these 
experiments could increase the ICAM-1 signal measured in cell culture supernatants from 
TNFα stimulated HUVEC. Therefore, the up-regulation of ICAM-1 secretion upon 
stimulation of HUVEC can not be used to determine Ang II signalling activity. 
Other sources also state that interleukin-8 (IL-8) production is increased upon 
stimulation of HUVECs with Ang II 35. Therefore, the supernatants of stimulated HUVECs 
were also tested for their IL-8 content. TNFα was again used as a positive control. As 
shown in Figure 23, TNFα stimulated cells secrete IL-8 into the supernatant. There is a 
slight increase in soluble IL-8 in the supernatant of HUVECs stimulated with 10-9M Ang II. 
However, here again, Ang II stimulation could not increase the signal significantly beyond 
control level.  
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Figure 23: Detection of soluble IL-8 in supernatants of stimulated HUVECs using a ready to 
use sandwich ELISA kit; supernatants of un-stimulated cells are shown in red, DMSO 
treated cells in yellow, TNFα stimulated cells in pink, and supernatants of cells stimulated 
with different concentrations of Ang II in dark to light blue.  
The results show that the approach using HUVECs for cell-based ELISA 
experiments to establish an in vitro assay for the determination of Ang II signalling activity 
was not successful. Therefore another signal read out had to be found that can be 
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increased upon stimulation of cells with Ang II. As described in the following chapter, the 
next approach focuses on the activation of NF-κB in HEK293 cells. 
3.2.2. Luciferase assay in HEK293  
The scheme of the in vitro assay linking Ang II signalling to a luminescence signal 
via NF-κB activation and luciferase expression is shown in Figure 24.  
 
Figure 24: Schematic view of Ang II stimulated NF-κB activation and subsequent luciferase 
expression via a reporter gene cassette containing several repeats of NF-κB response 
element 
Human embryonic kidney cells (HEK293) are used here, because they are easy to 
handle in FACS analysis and transfection. Most importantly, HEK293 cells express all the 
intracellular factors necessary for NF-κB activation. A NF-κB response-element luciferase 
reporter gene expression vector was used to measure NF-κB activation upon stimulation 
of HEK293 cells. Unfortunately, these cells do not endogenously express the AT1 
receptor. Therefore, an AT1R expression vector has to be introduced into the cells to 
render them susceptible to Ang II stimulation. In order to determine the efficiency of 
transfection of HEK293 cells with the NF-κB response-element luciferase reporter gene 
expression vector and the AT1R expression vector, the AT1 receptor was fused to EGFP. 
The green fluorescent signal of positively transfected cells was measured by fluorescence 
activated cell sorting (FACS). 
A CMV (cytomegalo virus) expression vector encoding the human angiotensin II 
type I receptor cDNA (variant 2) was obtained from Origene. This vector was used as a 
template for PCR as described in the materials & methods section. Simultaneously to the 
amplification reaction the coding region of the AT1R was excised from the vector template. 
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Primers used here contain recognition sites for the restriction enzymes EcoRI and BamHI 
at the 5’ and 3’ ends of the PCR product. These enzymes were chosen, because they cut 
within the multiple cloning site of most vectors and thus ease future cloning steps. The 
pEGFP-N1 vector contains an EcoRI and a BamHI recognition site, upstream of and in 
frame with the EGFP gene and thus allows the production of a C-terminal GFP-fusion 
protein. The product from the PCR reaction and the pEGFP-N1 expression vector were 
double-digested with EcoRI and BamHI and relegated together to give an AT1R-EGFP 
fusion protein (see Figure 25). 
 
 
The newly generated vector was transformed into E.coli DH5α and bacteria were selected 
for the successfully relegated pEGFP-N1 vector using 30µg/ml Kanamycin. To analyse 
the constructs produced by the ligation reaction, 6 different clones were picked for plasmid 
DNA extraction using the QIAgen Midiprep kit. Isolated plasmid DNA derived from 
different clones was double digested with EcoRI and BamHI to analyse the success of the 
plasmid DNA preparation and to determine whether the new vector contains the desired 
insert. The results were visualised using agarose gel electrophoresis (see Figure 26).  
Figure 25: Angiotensin II type I receptor EGFP fusion pro-
tein expression vector 
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Figure 26: EcoRI/ BamHI double digest of plasmid DNA derived from 6 different E.coli 
clones (Tango, BamHI, Ia, Ib, IIa, IIb) after MidiPrep (QIAgen) on a 1.2% agarose gel 
Figure 26 shows that the different plasmid DNA isolations containing AT1R-EGFP 
vector are digested into a ~1000bp and a ~5000bp fragment. AT1R variant 2 cDNA is 
1077bp long and the pEGFP-N1 vector without insert has 4.7kb. These results indicate 
that the ligation was successful and that the isolated plasmids encode AT1R as well as 
EGFP. 
To further confirm that the correct plasmid construct was isolated from E.coli, a 
sequence analysis was performed. The results of this analysis are shown in the appendix 
I. All sequences derived from PCR reaction with different primers are identical with the 
human AT1R cDNA variant 2 listed on the NCBI database, except for one nucleotide. This 
point mutation in position 572 of the AT1R gene is a wobble base and thus the amino acid 
at this position of the protein is not changed. These results further confirm that the isolated 
plasmids encode the AT1R-EGFP fusion protein. 
Next, the expression of this AT1R-EGFP fusion protein in HEK293 cells transfected 
with the isolated plasmid was determined via FACS analysis. As shown in Figure 27 
tranfected HEK293 cells show green fluorescent activity. This demonstrates that EGFP is 
expressed and fluorescently active and thus indicates that the AT1R-EGFP product is 
recognised as one translation frame.  
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Figure 27: FACS analysis of HEK293 cells transfected with AT1R-EGFP expression vector 
clone “tango” (A) and pEGFP-N1 (B) 
Figure 27 (A) shows that about 40% of HEK293 cells transfected with the AT1R-
EGFP expression vector have significant green fluorescent activity. This indicates that 
these cells express EGFP. Figure 27 (B) shows FACS analysis of HEK293 cells 
transfected with pEGFP-N1 without AT1R insert. Here, the fluorescent intensity is almost 
out of scale. 
The correct expression of the angiotensin II type I receptor in tranfected HEK293 
cells was also determined by Western Blot analysis. Three different anti- AT1R antibodies 
(all from Santa-Cruz Biotechnologies) were tested. However, no AT1R specific signal from 
HEK293 cell-lysates could be detected with any of these antibodies. An AT1R membrane 
isolation (PerkinElmer) and HUVEC lysates were used as positive controls for Western 
blot analysis of the AT1R. However, even within these positive controls there was no 
clearly specific AT1R signal visible on the nitrocellulose membrane. Therefore, an anti-
GFP (Abcam) antibody was used to detect the AT1R-EGFP fusion protein expressed in 
transfected cells. The results from the Western Blot analysis using this anti-GFP antibody 
are shown in Figure 28. 
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Figure 28: Lysates of un-transfected (wt), AT1R-EGFP transfected and EGFP transfected 
HEK293 cells; GFP has a molecular weight of 26.9kDa and the AT1R-EGFP fusion protein 
seems to be at a height of ~60kDa (red circle) 
The Western Blot of HEK293 cell-lysates after transfection with the empty EGFP 
vector or with the AT1R-EGFP encoding vector shows a GFP specific band at ~60kDa that 
is only present in AT1R-EGFP transfected cells. A second band recognised by the anti-
GFP antibody just above the usual GFP band at 27kDa might derive from a short 
translational by-product. The band at approximately 70kDa seems not to be GFP-specific, 
since it also occurs in wild type HEK293 cells.  
The AT1 receptor is a seven transmembrane receptor and should be expressed 
within the plasma membrane of the cells. HEK293 cells transfected with the AT1R-EGFP 
fusion vector were analysed by fluorescence microscopy to determine the cellular 
localisation of the expressed protein.  
 
Figure 29: Fluorescent microscopy images of HEK293 cells expressing the AT1R-EGFP 
fusion protein  
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The pictures taken with the fluorescence microscope (Figure 29) show, that the 
fluorescent activity of transfected HEK293 cells is concentrated in their cell membranes. 
This further indicates that the AT1R-EGFP fusion protein is correctly expressed and that 
the protein is localised within the cell membrane. Therefore, the AT1 receptor should be 
susceptible to stimulation with Ang II.  
After the integrity of the generated AT1R-EGFP construct was analysed by these 
numerated methods, it can be assumed that the receptor should be functionally active. 
This was assessed in a functional assay linking AT1R stimulation to the expression of a 
luciferase reporter gene via NF-κB activation. Ang II is known to activate the transcription 
factor NF-κB upon receptor binding. Activated NF-κB acts as a transcription factor on 
gene expression in the nucleus (see Figure 24). Therefore, a reporter cassette consisting 
of five repeats of the NF-κB response-element upstream of the Renilla luciferase gene 
(NFκB-luc) was inserted into HEK293 cells to work as a reporter gene system. The 
activation of NF-κB and the subsequent expression of luciferase were used to measure 
Ang II signalling via chemiluminescent luciferase activity.  
 
Figure 30: Luminescence of HEK293 cells co-transfected with NFκB-luc and empty EGFP 
(left) or AT1R-EGFP and NF-κB-luc (right) after 24h of stimulation with 10ng/ml TNFα or 10-
5M Ang II respectively 
It can be seen from Figure 30 that the stimulation of HEK293 cells transfected with 
AT1R-EGFP and NFκB-luc with Ang II significantly increases the luminescence signal. 
HEK293 cells transfected with NFκB-luc and the EGFP-N1 vector were used as a 
reference for NF-κB activity and stimulated with TNFα. Stimulation with TNFα as a 
positive control significantly increases the luciferase expression through NFκB-luc 
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activation. These results further indicate that the generated AT1R-EGFP fusion protein is 
expressed in the plasma-membrane of transfected cells and is functionally active.  
The measured luciferase signal should decrease when cotransfected HEK293 
cells are pre-incubated with AT1 receptor blocker losartan.  
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Figure 31: Luminescence of HEK293 cells co-transfected with NFκB-luc and empty EGFP 
(left) or AT1R-EGFP and NF-κB-luc (right) after 24h of stimulation with ■ 10ng/ml TNFα or ■ 
10-5M Ang II respectively or inhibited with ■ 10-7M losartan before 10-5M Ang II stimulation 
Figure 31 shows another luminescence experiment using co-transfected HEK293 cells. 
Stimulation of HEK293 cells co-transfected with AT1R-EGFP and NFκB-luc expression 
vectors with 10-5M Ang II results in a significant increase of luciferase activity. However, in 
this experiment the luminescence signal of Ang II stimulated cells is lower than in the 
previous experiment (see Figure 30). Incubation of HEK293 cells co-transfected with AT1R-
EGFP and NFκB-luc expression vectors with receptor blocker losartan prior to stimulation 
with Ang II, reduces the luciferase activity. HEK293 cells transfected with NFκB-luc and 
the EGFP-N1 vector were again used as a reference for NF-κB activity. However, neither 
Ang II nor losartan have any effect on HEK293 cells that are not transfected with the AT1 
receptor construct. 
Different concentrations of Ang II and TNFα were used to stimulate co-transfected 
HEK293 cells in order to determine the minimal amount of stimulus needed to significantly 
increase the luminescence. Furthermore, losartan should not affect the luciferase 
expression of HEK293 cells co-transfected with AT1R-EGFP and NFκB-luc expression 
vectors stimulated with TNFα. 
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Figure 32: Luminescence of HEK293 cells co-transfected with AT1R-EGFP and NF-κB-luc 
after 24h of stimulation with  5ng/ml TNFα or 10-5M- 10-9M Ang II respectively or inhibited 
with 10-4M losartan before stimulation 
Figure 32 shows that HEK293 cells co-transfected with AT1R-EGFP and NF-κB-luc 
can be stimulated to express luciferase with different concentrations of Ang II. The highest 
luminescence signal was measured after stimulation of HEK293 cells with 10-6M Ang II. 
Interestingly, even the lowest Ang II concentration used here (10-9M Ang II) could 
significantly stimulate luciferase expression. 10-4M losartan inhibits the activation of AT1R 
by Ang II. However, losartan has no effect on HEK293 cells stimulated with TNFα. This 
further indicates that the increase in luciferase expression upon stimulation of transfected 
HEk293 cells with Ang II is specific for AT1R activation and not due to other factors in the 
medium. 
Luciferase assays to determine the inhibitory capacity of Ang II- or Variotope®-
induced sera were conducted as well. However, the presence of mouse serum in the cell 
culture supernatant of HEK293 cells seems to have stimulatory effects on NF-κB 
activation. These effects have to be blocked to study the effect of Ang II specific 
antibodies on AT1R stimulation using NF-κB activation as read out. However, the 
possibilities to use mouse sera in the established lusiferase assay will have to be defined 
in future experiments.  
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4. Discussion 
4.1. Epitope specificity of Ang II-induced sera changes after multiple vaccination 
steps 
Three of the seven transmembrane domains and the linking extracellular loops of 
the AT1 receptor are involved in ligand interactions (see also Figure 33). Binding of Ang II 
to the AT1 receptor requires the interaction of the C- terminal phenylalanine side chain of 
Ang II with the histidine at position 256 of the receptor. This interaction is facilitated by 
docking the carboxyl-group to the lysine at position 199 of the AT1 receptor. The 
interaction at this, so called phenylalanine-switch locus is based on the stacking of the 
aromatic rings of Phe 8 and His 256. Any modification of these residues that would 
prevent the planar arrangement of the benzyl side chain above the Pro 7-Phe 8 amide 
bond has an antagonistic effect on receptor-binding. Interestingly, this loss of function is 
not consistent with a loss of affinity. Antagonists are known to have higher affinity to the 
AT1 receptor binding sites than most agonists. However, the stacking interaction of Phe 8 
and His 256 does not induce a large conformational change, but exposes other sites 
within the receptor for crucial interactions. The asparagine at position 111 within 
transmembrane helix III of AT1R is known to interact with the tyrosine at position 4 of the 
Ang II peptide. This interaction has been found to trigger the major conformational change 
that efficiently activates the AT1 receptor 26, 27. Therefore, any antibody able to block the 
binding of Ang II and the subsequent activation of AT1R might have to target the Tyr 4 and 
the C-terminal Phe 8 of the Ang II peptide.  
 
Figure 33: The angiotensin II type I receptor. Red Circles mark residues involved in Ang II 
binding: N111, K199, H256 
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The first ELISA experiments described in the results chapter were conducted to 
find whether the epitope specificity of Ang II-induced sera changes after multiple 
vaccination steps. The vaccination schedule consisting of one prime vaccination and three 
boost vaccinations is conducted to reach high antibody titres. Twelve days after each 
vaccination the serum of the mice is collected. Thus, Serum1, Serum2, Serum3 and the 
Endserum are obtained. The results show that titres rise from Serum1 to Serum3. 
However, after the third boost vaccination the titres do generally not increase significantly. 
One reason for this phenomenon might be that the immune response is directed towards 
more dominant epitopes of the carrier protein KLH. This shows the down-side of peptide-
based vaccines. The low immunogenicity of short sequences places a lower risk of 
inflammation side effects, but at the same time needs highly immunogenic carrier proteins 
that might reduce peptide-specific boosting effects. 
In Serum2 there is a significant difference in titres against Ang II variant peptides 
compared to the original Ang II peptide, especially if the C-terminal end of the octapeptide 
is modified. Any modification of the phenylalanine at position 8, the free carboxyl-group of 
the 8th amino acid and also the histidine at position 6 in the Ang II peptide results in 
reduced recognition of the antigenic determinant by Ang II-induced antibodies. This 
indicates that after the first boost vaccination the major humoral immune response is 
directed against the C-terminal end of Ang II. Furthermore, it allows us to assume that 
these residues might play an important role for C-terminal antibody binding. 
4.2. Reactivity of Variotope®-induced sera to Ang II and their crossreactivity to Ang 
I and Ang 1-7 
The repertoire of antigenic determinants of the Ang II peptide has been established by 
Picard et al. in 1986 using inhibition studies and radioimmunoassay. The monoclonal 
antibodies produced in these studies react to a great variety of antigenic determinants 
within the octapeptide. These antibodies were generated by immunisation of BALB/c mice 
with Val5-Ang II conjugated to KLH, isolation of lymphocytes from the spleens of 
responding mice and the generation of a hybridoma cell line for each lymphocyte clone. 
Picard and his group could identify monoclonal antibodies reacting to the C-terminal end 
(C-term) of the peptide that differ in their specificity for distinct parts of the C-term and in 
their crossreactivity to Ang I. One group of mAB required the phenylalanine at position 8 
as the terminal amino acid, another one reacted rather to the carboxy-terminal moiety 
than to the side chain of the terminal amino acid and yet another group was also reactive 
to Ang I, which carries two additional C-terminal amino acids. Additionally, 
radioimmunoassay showed that antibody binding was dramatically inhibited when the 
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tyrosine residue at position 4 was modified. Therefore, the C-terminal epitope probably 
encompasses both amino acids, the phenylalanine at position 8 and the tyrosine at 
position 4 28. A spiral model for isoleucyl-angiotensin II, published in 1962 by Smeby et al., 
supports this suggestion, because it describes the close apposition of the two aromatic 
rings of Tyr 4 and Phe 8 29. Figure 34 shows the most potential spiral arrangement of the 
Ang II octapeptide. 
 
Figure 34: Conformational model for Ang II showing the side chains of all eight residues; 
from the top: DRVYIHPF 
Ang II peptide variants can induce sera that show a significantly increased 
immunogenicity. In accordance with the results of Picard et al., immunisation with Ang II 
results in sera containing a variety of antibodies. The results from ELISA experiments 
presented in this work, show that mouse sera immunised with Ang II contain antibodies 
that react to different angiotensin peptides with different intensity. Although the oligoclonal 
antibody mixture in these sera specifically recognises the C-terminal end of the 
octapeptide, it can not distinguish between Ang II, Ang I or a peptide variant having an 
amydated carboxyl-group. The aim of the project is to induce oligoclonal antibodies that 
can distinguish between Ang II, Ang I and Ang 1-7 by immunisation with different Ang II-
peptide variants.   
Furthermore, the results from ELISA experiments with Variotope®-induced sera 
indicate that modifications in the central part of the octapeptide affect the selectivity for 
Ang II, as compared to the crossreactivity to Ang I and Ang 1-7. These central amino 
acids might play an important role for the affinity of induced antibodies for Ang II, Ang I 
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and Ang 1-7. Modifications of these central positions of the Ang II sequence might result 
in structural and conformational changes of the whole Ang II peptide. Especially the 
tyrosine at position 4 has been previously found to be part of the C-terminal epitope of 
Ang II. In peptide variants Ang II-066 and Ang II-067 tested in mice, the three middle 
residues of the Ang II sequence (DRVYIHPF) are exchanged to a neutral amino acid, 
forming a long sequence without reactive chemical properties. This structure could affect 
antibody binding, and direct the specificity towards Ang II, while excluding Ang I. These 
results are consistent in mouse- and rat-experiments. The most successful peptide (Ang 
II-030) in recognising Ang II while sparing Ang 1-7 and reducing the crossreactivity to Ang 
I in Wistar rats is also modified within these 3 residues. By specifically choosing 
exchanges at positions 2-5 (DRVYIHPF) we could achieve a reduction of the 
crossreactivity to Ang I and almost eliminate the crossreactivity to Ang 1-7. This might 
mean that middle and N-terminal residues play an important role in directing the antibody 
response towards the C-term and are not only mere spacers. However, Ang 1-7 is highly 
recognised when one or more of the last three residues (DRVYIHPF) are changed to 
alanine, thus directing the antibody respond towards the N-terminal end of the 
octapeptide. When exchanging one or more residues with various amino acids with similar 
or contrary chemical properties, we found that there are some Varitope®s that behave 
similar to the original peptide and some that differ from the original peptide in their 
recognition pattern to Ang I and Ang 1-7. 
4.3. Determination of Ang II signalling by functional cellular assay 
A variety of different experiments that define the effects of angiotensin II 
stimulation in different cell lines has been published. In these publications, mostly cells 
that endogenously express angiotensin receptors were used. These include vascular 
smooth muscle cells (VMSC), human umbilical vein cells (HUVEC), rat cardiac fibroblasts 
and mouse mesanglial cells (MMC). A group around Bin Wang detected the effect of Ang 
II on vascular smooth muscle cell (VSMC) proliferation via bromodeoxyuridine 
incorporation and cell cycle distribution. Furthermore, they measured the expression of c-
jun and c-fos (cellular markers for proliferation) mRNA in Ang II stimulated VSMC by 
reverse transcription PCR and Western Blot 30. Another method to determine the 
signalling activity of Ang II is to measure the intracellular free Ca2+ concentration. This is 
done using Ca2+ sensitive indicators, such as Fluo3-AM or Flura-2 AM, whose emitted 
fluorescent activity was analysed by a laser scanning confocal microscope 31, 32. 
Stimulation of the AT1R via Ang II activates several intracellular MAP kinases, whose 
phosphorylation state can also be used as indicator of Ang II signalling. The activation of 
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MAP kinases such as ERK1/2 or STAT3 is examined by Western Blot using phospho-
specific antibodies 32, 33, 34.  
The assay developed in this diploma thesis should be feasible, robust, easy to 
handle, allow medium through-put analysis and give a clear signal to noise ratio. 
Therefore, we looked for a signal read out that can be changed by Ang II treatment and 
that can be measured by a method that meets these criteria.  
Chae et al. measured the increase of ICAM-1 and VCAM-1 expression in HUVECs 
after Ang II stimulation by semi-quantitative RT-PCR analysis. Furthermore, they also 
measured the amount of cell-surface bound ICAM-1 and VCAM-1 molecules on HUVECs 
fixed on a 96 well plate by ELISA. This is an effective method that can be used for high 
through-put analysis. Chae et al. published a 1.5 fold increase of both adhesion molecules 
after Ang II stimulation 32. Furthermore, a cellular ELISA for the determination of ICAM-1 
and VCAM-1 expression in HUVECs was already used in house with another indication. 
However, in the project presented here, it was not possible to induce a significant 
difference in the amount of membrane expressed ICAM-1 and VCAM-1 molecules in 
HUVEC by stimulation with Ang II. A group around L. Pastore published that the secretion 
of soluble ICAM-1 is also significantly increased upon Ang II stimulation. The attempt to 
determine the amount of ICAM-1 molecules in the supernatant of stimulated HUVECs 
using a commercially available ICAM-1 sandwich ELISA kit was not successful. Moreover, 
the increased secretion of IL-8 after Ang II stimulation published for VSMCs by Kim et al. 
could not be seen from IL-8 sandwich ELISA of HUVEC-supernatants 35. Although all 
experiments have been conducted as described in the respective publications, the results 
described there could not be reproduced here. The interfering effect of the cell culture 
medium on the assay read out was not examined more closely, because the approach 
was stopped to focus on a potentially more successful method. 
Like many other G-protein coupled receptors, AT1R is known to form homo- and 
heterodimers. The formation of dimers regulates receptor-specific functions, such as 
ligand binding, signalling, desensitisation and cell surface targeting. Hypertensive patients 
have been found to show enhanced angiotensin II responsiveness. This might be due to 
elevated levels of crosslinked AT1 receptor dimers. An enzyme, called intracellular factor 
XIIIA transglutaminase crosslinks activated AT1R homodimers via glutamine at the C-
terminal tail of the receptor. Two G-protein coupled receptors can interact with one G-
protein. A crosslinked AT1R dimer may be kinetically favourable for G-protein interaction 
compared to a dissociable receptor complex, thereby accounting for enhanced activation 
and signalling. Formation of crosslinked AT1 receptor dimers requires the activation of the 
Ang II-AT1R system and of factor XIIIA 36. Therefore a signal (such as ICAM-1 or VCAM-1 
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expression) released by Ang II stimulation might be increased by crosslinking of the 
angiotensin II type I receptor. This can be achieved by addition of the crosslinking factor 
XIIIA transglutaminase into the cell medium. An approach stimulating crosslinked receptor 
dimers in HUVECs could probably be more successful in increasing ICAM-1, VCAM-1 or 
IL-8 expression. 
Other attempts to determine the activation of the AT1 receptor, measure the 
activation of NF-κB. This can be done directly via electrophoretic mobility shift assay 
(EMSA) characterising the binding activity of NF-κB in nuclear extracts to radio-labelled 
transcription factor consensus oligonucleotides or indirectly by measuring the degradation 
of IκB via Western Blot 37. Soehnlein et al. measured ICAM-1, VCAM-1 expression and 
NF-κB translocation into the nucleus via FACS analysis using fluorescently labelled 
antibodies to each of the desired proteins 38. As already mentioned, the measurement of 
ICAM-1 and VCAM-1 expression was not feasible for the application described here. 
Therefore we focused on methods to determine the activation of transcription factor NF-
κB. 
A very elegant experiment conducted by Wolf et al. uses a reporter gene cassette 
consisting of four tandem copies of the κ enhancer fused to the herpes simplex virus 
thymidine kinase promoter upstream of a luciferase gene to measure NF-κB activation. 
They transiently transfected COS7 cells (a kidney fibroblast cell line attained from 
Cercopithecus aethiops) with full-length rabbit AT1 receptor and pNF-κB-luc. These cells 
were then stimulated with 10-7M Ang II and the luciferase activity was measured.  This 
assay met the criteria of clear signal to noise ratio, possibility for medium through-put 
analysis and feasibility. Thus, in the second approach to establish an in vitro functional 
assay to determine Ang II signalling activity, we tried to reproduce the luciferase assay 
described by Wolf et al.39  
In this project, HEK293 cells were chosen, because they are easy to handle and to 
transfect. Most importantly, HEK293 cells possess all the intracellular signalling factors 
necessary to activate NF-κB upon an extracellular stimulus. However, HEK293 cells do 
not endogenously express the angiotensin II type I receptor. Therefore, the cells were 
transfected with a cyto-megalo virus vector expressing the AT1 receptor. In order to 
measure transfection efficiency via FACS the AT1 receptor was fused to the N-terminal 
end of EGFP. A fusion protein consisting of the angiotensin II type I receptor and GFP has 
been shown to be functionally active in a study by Hunyady and his group in 2002 40. The 
construct resulting from the ligation of the AT1R cDNA variant 2 into the pEGFP-N1 vector 
conducted in the present work was sequenced. Sequencing data reveal that, except for 
one point mutation in a wobble base at position 572 of the AT1R gene, the sequence of 
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the AT1 receptor and the EGFP gene are correct and within the same translation frame. 
Pointmutations in wobble bases usually do not change the amino acid at this position of 
the gene. This is also the case here, as codons CTT and CTC both encode leucine. The 
correct expression of the whole AT1R-EGFP fusion protein was further shown by Western 
Blot. The GFP specific band detected on the membrane using an anti-GFP antibody is 
about 10kDa lower than expected from addition of the mass of AT1R (~40kDa) and EGFP 
(27kDa). However, AT1R is a seven transmembrane receptor and these proteins are 
known to behave differently in SDS-PAGE analysis compared to average protein ladders.  
In this experiment an anti-GFP antibody was used to detect the expression of the AT1R-
EGFP, because the anti-AT1R antibodies available in this project did not give a specific 
signal in Western blot analysis. Fluorescence microscopy of HEK293 cells transfected 
with the AT1R-EGFP expression vector showed that the green fluorescent activity of the 
cells is concentrated on the cell membrane. Thus, we can assume that the receptor is 
expressed in the cell membrane of transiently transfected HEK293 cells. There, it should 
be functionally active. Furthermore, cells transfected with the AT1R-EGFP expression 
vector showed fluorescent activity in the FACS analysis. However, compared to the 
fluorescent activity of HEK293 cells transfected with the pEGFP-N1 vector alone, the 
signal is decreased. This might indicate that the whole fusion protein is expressed and 
thus GFP activity is obscured. Moreover, stimulation of transfected cells with Ang II 
induced a significant luciferase activity increase according to NF-κB activation. This signal 
increase was reversible by incubation of transfected cells with AT1R inhibitor losartan. 
This shows that the signal increase is specific for Ang II stimulation and not due to any 
other stimulatory substance in the cell culture- medium. Losartan even decreased the 
signal below the background level of unstimulated cells. This might indicate that unspecific 
activation of NF-κB occurred due to any assay procedures and that this unspecific 
activation was also reversed by losartan. In summary these data indicate that the AT1R-
EGFP vector was expressed correctly and functionally active in transiently transfected 
HEK293 cells. 
Preliminary experiments determining the inhibitory capacity of Ang II- or 
Variotope®-induced sera were conducted as well. However, the presence of mouse 
serum in the cell culture supernatant of HEK293 cells alone, seems to affect NF-κB 
activation. The stimulatory effects of complete mouse sera have to be blocked to study the 
effect of antibodies contained in these sera on Ang II-AT1R binding. It is not clear which 
component of complete mouse serum stimulates NF-κB activation in HEK293 cells. IgG 
molecules alone should not activate NF-κB in HEK293 cells, since these cells do not 
express any Fc-receptors. Thus, Ang II specific antibodies contained in the mouse sera 
will have to be isolated or immobilised using for example protein A. However, the 
possibilities to use mouse sera in the established lusiferase assay will have to be defined 
in future experiments. 
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Appendix I 
Sequence analysis: 
Alignment of AT1R-EGFP sequence with sequencing data from AT1R-EGFP tango 
Original−AATGTCGTAACAACTCCGCCCCATTGACGCAAATGGGCGGTAGGCGTGTACGGTGGGAGGTCTATATAAGCAGAGCTGGTT  81 
Fw2--------------------------------------------------------------------------------------- 
Fw3--------------------------------------------------------------------------------------- 
Fw4--------------------------------------------------------------------------------------- 
Fw5--------------------------------------------------------------------------------------- 
Rev2-----AATGTCGTAACAACTCCGCCCCATTGACGCAAATGGGCGGTAGGCGTGTACGGTGGGAGGTCTATATAAGCAGAGCTGGTT   
Rev3-------------------------------------------------------------------------------------- 
Rev4-------------------------------------------------------------------------------------- 
 
Original−TAGTGAACCGTCAGATCCGCTAGCGCTACCGGACTCAGATCTCGAGCTCAAGCTTCGAATTCATGATTCTCAACTCTTCTA 162 
Fw2----------------------------------------------CTCGAGCTCAAGCTTCGAATTCATGATTCTCAACTCTTCTA 
Fw3--------------------------------------------------------------------------------------- 
Fw4--------------------------------------------------------------------------------------- 
Fw5--------------------------------------------------------------------------------------- 
Rev2-----TAGTGAACCGTCAGATCCGCTAGCGCTACCGGACTCAGNTCTCGAGCTCAAGCTTCGAATTCATGATTCTCAACTCTTCTA 
Rev3-------------------------------------------------------------------------------------- 
Rev4-------------------------------------------------------------------------------------- 
 
Original−CTGAAGATGGTATTAAAAGAATCCAAGATGATTGTCCCAAAGCTGGAAGGCATAATTACATATTTGTCATGATTCCTACTT 243 
Fw2------CTGAAGATGGTATTAAAAGAATCCAAGATGATTGTCCCAAAGCTGGAAGGCATAATTACATATTTGTCATGATTCCTACTT 
Fw3--------------------------------------------------------------------------------------- 
Fw4--------------------------------------------------------------------------------------- 
Fw5--------------------------------------------------------------------------------------- 
Rev2-----CTGAAGATGGTATTAAAAGAATCCAAGATGATTGTCCCAAAGC-KGAAGGCATAATTACATATTTGTCATGATTCCTACTT 
Rev3-------------------------------------------------------------------------------------- 
Rev4-------------------------------------------------------------------------------------- 
  
Original−TATACAGTATCATCTTTGTGGTGGGAATATTTGGAAACAGCTTGGTGGTGATAGTCATTTACTTTTATATGAAGCTGAAGA 324 
Fw2------TATACAGTATCATCTTTGTGGTGGGAATATTTGGAAACAGCTTGGTGGTGATAGTCATTTACTTTTATATGAAGCTGAAGA 
Fw3--------------------------------------------------------------------------------------- 
Fw4--------------------------------------------------------------------------------------- 
Fw5--------------------------------------------------------------------------------------- 
Rev2-----TATACAGTATC---------------------------------------------------------------------- 
Rev3-------------------------------------------------------------------------------------- 
Rev4-------------------------------------------------------------------------------------- 
 
Original−CTGTGGCCAGTGTTTTTCTTTTGAATTTAGCACTGGCTGACTTATGCTTTTTACTGACTTTGCCACTATGGGCTGTCTACA 405 
Fw2------CTGTGGCCAGTGTTTTTCTTTTGAATTTAGCACTGGCTGACTTATGCTTTTTACTGACTTTGCCACTATGGGCTGTCTACA 
Fw3--------------------------------------------------------------------------------------- 
Fw4--------------------------------------------------------------------------------------- 
Fw5--------------------------------------------------------------------------------------- 
Rev2-------------------------------------------------------------------------------------- 
Rev3-------------------------------------------------------------------------------------- 
Rev4-------------------------------------------------------------------------------------- 
 
Original−CAGCTATGGAATACCGCTGGCCCTTTGGCAATTACCTATGTAAGATTGCTTCAGCCAGCGTCAGTTTCAACCTGTACGCTA 486 
Fw2------CAGCTATGGAATACCGCTGGCCCTTTGGCAATTACCTATGTAAGATTGCTTCAGCCAGCGTCAGTTTCAACCTGTACGCTA 
Fw3--------------------------------------------------------------------------------------- 
Fw4--------------------------------------------------------------------------------------- 
Fw5--------------------------------------------------------------------------------------- 
Rev2-------------------------------------------------------------------------------------- 
Rev3-------------------------------------------------------------------------------------- 
Rev4-------------------------------------------------------------------------------------- 
 
Original−GTGTGTTTCTACTCACGTGTCTCAGCATTGATCGATACCTGGCTATTGTTCACCCAATGAAGTCCCGCCTTCGACGCACAA 567 
Fw2------GTGTGTTTCTACTCACGTGTCTCAGCATTGATCGATACCTGGCTATTGTTCACCCAATGAAGTCCCGCCTTCGACGCACAA 
Fw3--------------------------------------------------------------------------------------- 
Fw4--------------------------------------------------------------------------------------- 
Fw5--------------------------------------------------------------------------------------- 
Rev2-------------------------------------------------------------------------------------- 
Rev3-------------------------------------------------------------------------------------- 
Rev4-------------------------------------------------------------------------------------- 
 
Original−TGCTTGTAGCCAAAGTCACCTGCATCATCATTTGGCTGCTGGCAGGCTTGGCCAGTTTGCCAGCTATAATCCATCGAAATG 648 
Fw2------TGCTTGTAGCCAAAGTCACCTGCATCATCATTTGGCTGCTGGCAGGCTTGGCCAGTTTGCCAGCTATAATCCATCGAAATG 
Fw3------------------------------------TTTGGCTGCTGGCAGGCTTGGCCAGTTTGCC GCTATAATCCATCGAAATG 
Fw4--------------------------------------------------------------------------------------- 
Fw5--------------------------------------------------------------------------------------- 
Rev2-------------------------------------------------------------------------------------- 
Rev3--------------------------------TCATTTGGCTGCTGGCAGGCTTGGCCAGTTTGCCAGCTATAATCCATCGAAATG 
Rev4-------------------------------------------------------------------------------------- 
 
Original−TATTTTTCATTGAGAACACCAATATTACAGTTTGTGCTTTCCATTATGAGTCCCAAAATTCAACCCTCCCGATAGGGCTGG 729 
Fw2------TATTTTTCATTGAGAACACCAATATTACAGTTTGTGCTTTCCATTATGAGTCCCAAAATTCAACCCTTCCGATAGGGCTGG 
Fw3------TATTTTTC TTGAGAACACCAATATTACAGTTTGTGCTTTCCATTATGAGTCCCAAAATTCAACCCTTCCGATAGGGCTGG 
Fw4--------------------------------------------------------------------------------------- 
Fw5--------------------------------------------------------------------------------------- 
Rev2-------------------------------------------------------------------------------------- 
Rev3-----TATTTTTCATTGAGAACACCAATATTACAGTTTGTGCTTTCCATTATGAGTCCCAAAATTCAACCCTTCCGATAGGGCTGG 
Rev4-------------------------------------------------------------------------------------- 
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Original−GCCTGACCAAAAATATACTGGGTTTCCTGTTTCCTTTTCTGATCATTCTTACAAGTTATACTCTTATTTGGAAGGCCCTAA 810 
Fw2------GCCTGACCAAAAATATACTGGGTTTCCTGTTTCCTTTTCTGATCATTCTTACAAGTTATACTCTTATTTGGAAGGNCCTAA 
Fw3------GCCTGACCAAAAATATACTGGGTTTCCTGTTTCCTTTTCTGATCATTCTTACAAGTTATACTCTTATTTGGAAGGCCCTAA 
Fw4--------------------------------------------------------------------------------------- 
Fw5--------------------------------------------------------------------------------------- 
Rev2-------------------------------------------------------------------------------------- 
Rev3-----GCCTGACCAAAAATATACTGGGTTTCCTGTTTCCTTTTCTGATCATTCTTACAAGTTATACTCTTATTTGGAAGGCCCTAA 
Rev4-------------------------------------------------------------------------------------- 
 
Original−AGAAGGCTTATGAAATTCAGAAGAACAAACCAAGAAATGATGATATTTTTAAGATAATTATGGCAATTGTGCTTTTCTTTT 891 
Fw2------AGAANGCTTATGAAATTCAGAAGAACAAACCAAGAAATGATGATATTTTTAAGATA------------------------- 
Fw3------AGAAGGCTTATGAAATTCAGAAGAACAAACCAAGAAATGATGATATTTTTAAGATAATTATGGCAATTGTGCTTTTCTTTT 
Fw4--------------------------------------------------------------------------------------- 
Fw5--------------------------------------------------------------------------------------- 
Rev2-------------------------------------------------------------------------------------- 
Rev3-----AGAAGGCTTATGAAATTCAGAAGAACAAACCAAGAAATGATGATATTTTTAAGATAATTATGGCAATTGTGCTTTTCTTTT 
Rev4-------------------------------------------------------------------------------------- 
 
Original−TCTTTTCCTGGATTCCCCACCAAATATTCACTTTTCTGGATGTATTGATTCAACTAGGCATCATACGTGACTGTAGAATTG 972 
Fw2--------------------------------------------------------------------------------------- 
Fw3------TCTTTTCCTGGATTCCCCACCAAATATTCACTTTTCTGGATGTATTGATTCAACTAGGCATCATACGTGACTGTAGAATTG 
Fw4--------------------------------------------------------------------------------------- 
Fw5--------------------------------------------------------------------------------------- 
Rev2-------------------------------------------------------------------------------------- 
Rev3-----TCTTTTCCTGGATTCCCCACCAAATATTCACTTTTCTGGATGTATTGATTCAACTAGGCATCATACGTGACTGTAGAATTG 
Rev4-------------------------------------------------------------------------------------- 
 
Original−CAGATATTGTGGACACGGCCATGCCTATCACCATTTGTATAGCTTATTTTAACAATTGCCTGAATCCTCTTTTTTATGGCT1053 
Fw2--------------------------------------------------------------------------------------- 
Fw3------CAGATATTGTGGACACGGCCATGCCTATCACCATTTGTATAGCTTATTTTAACAATTGCCTGAATCCTCTTTTTTATGGCT 
Fw4--------------------------------------------------------------------------------------- 
Fw5--------------------------------------------------------------------------------------- 
Rev2-------------------------------------------------------------------------------------- 
Rev3-----CAGATATTGTGGACACGGCCATGCCTATCACCATTTGTATAGCTTATTTTAACAATTGCCTGAATCCTCTTTTTTATGGCT 
Rev4-------------------------------------------------------------------------------------- 
 
Original−TTCTGGGGAAAAAATTTAAAAGATATTTTCTCCAGCTTCTAAAATATATTCCCCCAAAAGCCAAATCCCACTCAAACCTTT1134 
Fw2--------------------------------------------------------------------------------------- 
Fw3------TTCTGGGGAAAAAATTTAAAAGATATTTTCTCCAGCTTCTAAAATATATTCCCCCAAAAGCCAAATCCCACTCAAACCTTT 
Fw4--------------------------------------------------------------------------------------- 
Fw5--------------------------------------------------------------------------------------- 
Rev2-------------------------------------------------------------------------------------- 
Rev3-----TTCTGGGGAAAAAATTTAAAAGATATTTTCTCCAGCTTCTAAAATATATTCCCCCAAAAGCCAAATCCCACTCAAACCTTT 
Rev4-------------------------------------------------------------------------------------- 
 
Original−CAACAAAAATGAGCACGCTTTCCTACCGCCCCTCAGATAATGTAAGCTCATCCACCAAGAAGCCTGCACCATGTTTTGAGG1215 
Fw2--------------------------------------------------------------------------------------- 
Fw3------CAACAAAAATGAGCACGCTTTCCTACCGCCCCTCAGATAATGTAAGCTCATCCACCAAGAAGCCTGCACCATGTTTTGAGG 
Fw4---------CAAAAATGAGCACGCTTTCCTACCGCCCCTCAGATAATGTAAGCTCATCCACCAAGAAGCCTGCACCATGTTTTGAGG 
Fw5--------------------------------------------------------------------------------------- 
Rev2-------------------------------------------------------------------------------------- 
Rev3-----CAACAAAAATGAGCACGCTTTCCTACCGCCCCTCAGATAATGTAAGCTCATCCACCAAGAAGCCTGCACCATGTTTTGAGG 
Rev4-------------------------------------------------------------------------------------- 
 
Original−TTGAGGATCCACCGGTCGCCACCATGGTGAGCAAGGGCGAGGAGCTGTTCACCGGGGTGGTGCCCATCCTGGTCGAGCTGG1296 
Fw2--------------------------------------------------------------------------------------- 
Fw3------TTGAGGATCCACCGGTCGCCACCATGGTGAGCAAGGGCGAGGAGCTGTTCACCGGGGTGGTGCCCATCCTGGTCGAGCTGG 
Fw4------TTGAGGATCCACCGGTCGCCACCATGGTGAGCAAGGGCGAGGAGCTGTTCACCGGGGTGGTGCCCATCCTGGTCGAGCTGG 
Fw5--------------------------------------------------------------------------------------- 
Rev2-------------------------------------------------------------------------------------- 
Rev3-----TTGAGGATCCACCGGTCGCCACCATGGTGAGCAAGGGCGAGGAGCTGTTCACCGGGGTGGTGCCCATCCTGGTCGAGC--- 
Rev4------TGAGGATCCACCGGTCGCCACCATGGTGAGCAAGGGCGAGGAGCTGTTCACCGGGGTGGTGCCCATCCTGGTCGAGCTGG 
 
Original−ACGGCGACGTAAACGGCCACAAGTTCAGCGTGTCCGGCGAGGGCGAGGGCGATGCCACCTACGGCAAGCTGACCCTGAAGT1377 
Fw2--------------------------------------------------------------------------------------- 
Fw3------ACGGCGACGTAAACGGCCACAAGTTCAGCGTGTCCGGCGAGGGCGAGGGCGATGCCACCTACGGCAAGCTGACCCTGAAGT 
Fw4------ACGGCGACGTAAACGGCCACAAGTTCAGCGTGTCCGGCGAGGGCGAGGGCGATGCCACCTACGGCAAGCTGACCCTGAAGT 
Fw5--------------------------------------------------------------------------------------- 
Rev2-------------------------------------------------------------------------------------- 
Rev3-------------------------------------------------------------------------------------- 
Rev4-----ACGGCGACGTAAACGGCCACAAGTTCAGCGTGTCCGGCGAGGGCGAGGGCGATGCCACCTACGGCAAGCTGACCCTGAAGT 
 
Original−TCATCTGCACCACCGGCAAGCTGCCCGTGCCCTGGCCCACCCTCGTGACCACCCTGACCTACGGCGTGCAGTGCTTCAGCC1458 
Fw2--------------------------------------------------------------------------------------- 
Fw3------TCATCTGCACCACCGGCAAGCTGCCCGTGCCCTGGCCCACCCTCG------------------------------------ 
Fw4------TCATCTGCACCACCGGCAAGCTGCCCGTGCCCTGGCCCACCCTCGTGACCACCCTGACCTACGGCGTGCAGTGCTTCAGCC 
Fw5--------------------------------------------------------------------------------------- 
Rev2-------------------------------------------------------------------------------------- 
Rev3-------------------------------------------------------------------------------------- 
Rev4-----TCATCTGCACCACCGGCAAGCTGCCCGTGCCCTGGCCCACCCTCGTGACCACCCTGACNTACGGCGTGCAGTGCTTCAGCC 
 
Original−GCTACCCCGACCACATGAAGCAGCACGACTTCTTCAAGTCCGCCATGCCCGAAGGCTACGTCCAGGAGCGCACCATCTTCT1539 
Fw2--------------------------------------------------------------------------------------- 
Fw3--------------------------------------------------------------------------------------- 
Fw4------GCTACCCCGACCACATGAAGCAGCACGACTTCTTCAAGTCCGCCATGCCCGAAGGCTACGTCCAGGAGCGCACCATCTTCT 
Fw5--------------------------------------------------------------------------------------- 
Rev2-------------------------------------------------------------------------------------- 
Rev3-------------------------------------------------------------------------------------- 
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Rev4-----GCTACCCCGACCACATGAAGCAGCACGACTTCTTCAAGTCCGCCATGCCCGAAGGCTACGTCCAGGAGCGCACCATCTTCT 
 
 
 
 
 
 
Original−TCAAGGACGACGGCAACTACAAGACCCGCGCCGAGGTGAAGTTCGAGGGCGACACCCTGGTGAACCGCATCGAGCTGAAGG1620 
Fw2--------------------------------------------------------------------------------------- 
Fw3--------------------------------------------------------------------------------------- 
Fw4------TCAAGGACGACGGCAACTACAAGACCCGCGCCGAGGTGAAGTTCGAGGGCGACACCCTGGTGAACCGCATCGAGCTGAAGG 
Fw5--------------------------------------------------------------------------------------- 
Rev2-------------------------------------------------------------------------------------- 
Rev3-------------------------------------------------------------------------------------- 
Rev4-----TCAAGGACGACGGCAACTACAAGACCCGCGCCGAGGTGAAGTTCGAGGGCGACACCCTGGTGAACCGCATCGAGCTGAAGG 
 
Original−GCATCGACTTCAAGGAGGACGGCAACATCCTGGGGCACAAGCTGGAGTACAACTACAACAGCCACAACGTCTATATCATGG1701 
Fw2--------------------------------------------------------------------------------------- 
Fw3--------------------------------------------------------------------------------------- 
Fw4------GCATCGACTTCAAGGAGGACGGCAACATCCTGGGGCACAAGCTGGAGTACAACTACAACAGCCACAACGTCTATATCATGG 
Fw5--------------------------------------------------------------------------------------- 
Rev2-------------------------------------------------------------------------------------- 
Rev3-------------------------------------------------------------------------------------- 
Rev4-----GCATCGACTTCAAGGAGGACGGCAACATCCTGGGGCACAAGCTGGAGTACAACTACAACAGCCACAACGTCTATATCATGG 
 
Original−CCGACAAGCAGAAGAACGGCATCAAGGTGAACTTCAAGATCCGCCACAACATCGAGGACGGCAGCGTGCAGCTCGCCGACC1782 
Fw2--------------------------------------------------------------------------------------- 
Fw3--------------------------------------------------------------------------------------- 
Fw4------CCGACAAGCAGAAGAACGGCATCAAGGTGAACTTCAAGATCCGCCACAACATCGAGGACGGCAGCGTGCAGCTCGCCGACC 
Fw5----------------------------------------------------CAACATCGAGGACGGCAGCGTGCAGCTCGCCGACC 
Rev2-------------------------------------------------------------------------------------- 
Rev3-------------------------------------------------------------------------------------- 
Rev4-----CCGACAAGCAGAAGAACGGCATCAAGGTGAACTTCAAGATCCGCCACAACATCGAGGACGGCAGCGTGCAGCTCGCCGACC 
 
Original−ACTACCAGCAGAACACCCCCATCGGCGACGGCCCCGTGCTGCTGCCCGACAACCACTACCTGAGCACCCAGTCCGCCCTGA1863 
Fw2--------------------------------------------------------------------------------------- 
Fw3--------------------------------------------------------------------------------------- 
Fw4------ACTACCAGCAGAACACCCCCATCGGCGACGGCCCCGTGCTGCTGCCCGACAACCACTACCTGAGCACCCAGTCCGCCCTGA 
Fw5------ACTACCAGCAGAACACCCCCATCGGCGACGGCCCCGTGCTGCTGCCCGACAACCACTACCTGAGCACCCAGTCCGCCCTGA 
Rev2-------------------------------------------------------------------------------------- 
Rev3-------------------------------------------------------------------------------------- 
Rev4-----ACTACCAGCAGAACACCCCCATCGGCGACGGCCCCGTGCTGCTGCCCGACAACCACTACCTGAGCACCCAGTCCGCCCTGA 
 
Original−GCAAAGACCCCAACGAGAAGCGCGATCACATGGTCCTGCTGGAGTTCGTGACCGCCGCCGGGATCACTCTCGGCATGGACG1944 
Fw2--------------------------------------------------------------------------------------- 
Fw3--------------------------------------------------------------------------------------- 
Fw4------GCAAAGACCCCAACGAGAAGCGCGATCACATGGTCCTGCTGGAGTTCGTGACCG--------------------------- 
Fw5------GCAAAGACCCCAACGAGAAGCGCGATCACATGGTCCTGCTGGAGTTCGTGACCGCCGCCGGGATCACTCTCGGCATGGACG 
Rev2-------------------------------------------------------------------------------------- 
Rev3-------------------------------------------------------------------------------------- 
Rev4-----GCAAAGACCCCAACGAGAAGCGCGATCACATGGTCCTGCTGGAGTTCGTGACCGCCGCCGGGATCACTCTCGGCATGGACG 
 
Original−AGCTGTACAAGTAAAGCGGCCGCGACTCTAGATCATAATCAGCCATACCACATTTGTAGAGGTTTTACTTGCTTTAAAAAA2025 
Fw2--------------------------------------------------------------------------------------- 
Fw3--------------------------------------------------------------------------------------- 
Fw4--------------------------------------------------------------------------------------- 
Fw5------AGCTGTACAAGTAAAGCGGCCGCGACTCTAGATCATAATCAGCCATACCACATTTGTAGAGGTTTTACTTGCTTTAAAAAA 
Rev2-------------------------------------------------------------------------------------- 
Rev3-------------------------------------------------------------------------------------- 
Rev4-----AGCTGTACAAGTAAAGCGGCCGCGACTCTAGATCATAATCAGCCATACCACATTTGTAGAGGTTTTACTTGCTTTAAAAAA 
 
Original−CCTCCCACACCTCCCCCTGAACCTGAAACATAAAATGAATGCAATTGTTGTTGTTAACTTG 2086 
Fw2-------------------------------------------------------------------- 
Fw3-------------------------------------------------------------------- 
Fw4-------------------------------------------------------------------- 
Fw5------CCTCCCACACCTCCCCCTGAACCTGAAACATAAAATGAATGCAATTGTTGTTGTTAACTTG 
Rev2------------------------------------------------------------------- 
Rev3------------------------------------------------------------------- 
Rev4-----CCTCCCACACCTCCC------ 
Appendix I: The original sequence of the AGTR1 cDNA variant 2, used as a reference here, was 
obtained from the NCBI nucleotide database (NM_009585.3). The sequence of the pEGFP-N1 
vector can be found at the Addgene vector database (www.addgene.org).  
Forward primer sequences are highlighted in grey; Reverse primer sequences are highlighted in 
dark green; Start and stop codons of the AT1R and the EGFP gene are highlighted in bright green; 
Restriction enzyme recognition sites are highlighted in yellow and the point mutation in the wobble 
base at position 572 of the AT1R gene is highlighted in red. Red underlined letters are positions 
that could not be clearly identified. 
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Appendix II: Abbreviations 
7-AAD 7-aminoactinomycin D 
aa amino acid 
ABTS 2,2’-Aznobis-(3-ethylbenzthiazolin-6-sulfonic acid) 
ACE angiotensin converting enzyme 
ADAM17 a disintegrin and metalloproteinase 17 
ADH antidiuretic hormone 
AGT angiotensinogen 
Akt protein kinase B 
Alum aluminium hydroxide 
Ang I angiotensin I 
Ang II angiotensin II 
Ang 1-7 angiotensin (1-7) 
Ang1-9 angiotensin (1-9) 
Ang III angiotensin III 
Ang IV angiotensin IV 
ARAP1 type 1 Ang II receptor associated protein 1 
ARB angiotensin II receptor blockers 
Asn asparagine, N 
AT1R angiotensin II type I receptor 
AT2R angiotensin II type II receptor  
ATRAP AT1-receptor associated protein  
BGG Bovine Gamma Globulin 
BP Blood Pressure 
BSA Bovine Serum Albumin 
cAMP cyclic adenosine monophosphate 
cDNA complementary desoxyribunucleic acid 
CMV cytomegalo virus 
C-term Carboxy-terminal end 
CVD cardiovascular disease 
DAG diacylglycerol 
DMEM Dulbecco’s Modified Eagle’s Medium 
DMSO dimethylsulfoxid 
DNA desoxyribunucleic acid 
dNTP desoxyribonucleotide triphosphate 
DT Diphtheria Toxin 
ECL enhanced luminol-based chemi-luminescent substrate 
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EDTA Ethylene Diamine Tetraacetic Acid 
EGF Epidermal Growth Factor 
EGFP Enhanced Green Fluorescent Protein 
EGFR Epidermal Growth Factor Receptor 
ELISA Enzyme Linked Immunosorbent Assay 
ERK2 extracellular signal related kinases 
FACS Fluorescent-Activated Cell Sorting 
FCS Foetal Calf Serum 
FGF Fibroblast Growth Factor 
FSC-H forward scatter 
GDP guanosine diphosphate 
GFP Green Fluorescent Protein 
GMBS Maleimidobutyryloxy-Succinimide ester 
GST Glutathione S-Transferase 
GTP guanosine triphosphate 
HAEC Human Aortic Endothelial Cell 
HB-EGF Heparin-Binding EGF 
HEK Human Embryonic Kidney 
Hepes 2-(4-(2-Hydroxyethyl)-1-piperazinyl)-ethansulfonsäure 
His histidine, H 
HUVEC Human Umbilical Vein Endothelial Cell 
ICAM-1 Intracellular Adhesion Molecule-1 
IgG immunoglobulin G 
IL interleukin 
IP3 inositol triphosphate 
IRAP Insulin-Regulated Aminopeptidase Receptor; AT4R 
JNK c-Jun N-terminal kinases 
KLH Keyhole Limpet Hemocyanin 
LB Lysogeny Broth 
Lys lysine, K 
MAP Mitogen-Activated Protein 
MAS mas oncogen product 
MCS Multiple Cloning Site 
MEK MAP/ ERK kinase 
MMC Mouse Mesanglial Cell 
MMP matrix metalloproteinase 
mRNA messenger ribonucleic acid 
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NADPH nox-base nicotinamide adenosine dinucleotide phosphate 
NF-κB Nuclear Factor κB 
NFκB-luc NF-κB response element luciferase gene cassette 
NO Nitric Oxide 
N-term Amino-terminal end 
OD Optical Density 
PAGE  Poyacrylamide Gel-Electrophoresis 
PBS Phosphate Buffered Saline 
PCR Polymerase Chain Reaction 
Phe phenylalanine, F 
PI3K Phosphoinositid-3 Kinase 
PKC Protein Kinase C 
Pro proline, P 
Raf-1 v-raf oncogen murine leukemia viral oncogene homolog 1 
Ras rat sarcoma 
RAS Renin-Angiotensin System 
ROCK Rho kinase 
ROS Reactive Oxygen Species 
RT Room Temperature 
SDS Sodium Dodecyl Sulfate 
SHP-2 Src homology 2-containing inositol phosphatase 2 
SSC-H side scatter 
TAE Tris Acetic acid EDTA 
TBST Tris Buffered Saline Tween20 
TEMED N,N,N’,N’-Tetramethylethylenediamide 
TNFα Tumour Necrosis Factor α 
TT Tetanus Toxoid 
Tyr tyrosine, Y 
UV Ultra Violet 
Val valine, V 
VCAM-1 Vascular Cell Adhesion Molecule-1 
VSMC Vascular Smooth Muscle Cell 
WHO World Health Organisation 
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Date of birth: 04.11.1985  
Place of birth: Vienna 
Nationality: Austria 
Address: Schwindgasse 17/7, A-1040 Vienna, Austria 
Tel.: +431 9619581 10; +4369911291455 
Email: a0300503@unet.univie.ac.at 
       
 
 
Special skills: basic computer skills, skiing instructor allowed accompanying school 
skiing trips, driving licence, chemical and biological laboratory skills, fluent in English and 
German 
 
Education: 
May 2003 School leaving examination at “Gymnasium Sacré- Coeur” Vienna 
Oct 1st 2003 Start of academic studies of Molecular Biology in Vienna 
July 2005 Internship with the Institute of Parasitology of the Medical University 
of Vienna with Dr. Julia Walochnik:  
“ITS1 sequence variabilities correlate with 18s rDNA sequence 
types in the genus Acanthamoeba” 
sterile work with Acanthamoeba cultures; DNA isolation, sequencing 
and phylogenetic analysis using online databases and analysis 
programs 
July 2006 Practical with Ao. Univ. Prof. Dr. Timothy Skern at the Institute of 
Biochemistry of the Medical University of Vienna:  
“Defining residues involved in human rhinovirus 2A protease 
substrate recognition” 
plasmid restriction & ligation, cloning in E.coli, in vitro transcription, 
in vitro translation, PAGE  
 
Curriculum vitae 
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Sept. 2006- June 
2007 
Studentship of the European student exchange program  
ERASMUS at the University of Glasgow, Scotland 
October 15th- 
December 15th 2006 
Practical at the Division of Infection and Immunity at the University 
of Glasgow with Professor Sylke Muller:  
“Expression, purification and activity-assay of lipoate protein ligase 
A (LplA) from Escherichia coli and Plasmodium falciparum.” 
WB, SDS-PAGE, protein expression, colorimetric activity assay 
July 1st- August 31st 
2007 
Internship at Böhringer-Ingelheim in Vienna: 
sterile work with tumour cell cultures, 2D & 3D proliferation assay, 
kinase activity assay 
October 2008- June 
2009 
Diploma project with AFFiRiS AG: 
„Evaluation of candidate peptides for the immunization against 
angiotensin II”  
ELISA, SDS-PAGE, WB, generation of a GFP-fusion protein, 
establishment of a cellular assay for the determination of receptor 
functionality/ signalling Mode of Action using luciferase activity  
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